US20180016338A1 - Anti ceacam1 antibodies and methods of using same - Google Patents
Anti ceacam1 antibodies and methods of using same Download PDFInfo
- Publication number
- US20180016338A1 US20180016338A1 US15/715,386 US201715715386A US2018016338A1 US 20180016338 A1 US20180016338 A1 US 20180016338A1 US 201715715386 A US201715715386 A US 201715715386A US 2018016338 A1 US2018016338 A1 US 2018016338A1
- Authority
- US
- United States
- Prior art keywords
- antibody
- ceacam1
- cancer
- subject
- antibody fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 108
- 108010062802 CD66 antigens Proteins 0.000 title claims description 110
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 18
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims description 105
- 210000004027 cell Anatomy 0.000 claims description 88
- 206010028980 Neoplasm Diseases 0.000 claims description 52
- 201000011510 cancer Diseases 0.000 claims description 42
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 41
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 41
- 210000004698 lymphocyte Anatomy 0.000 claims description 32
- 201000001441 melanoma Diseases 0.000 claims description 25
- 230000002401 inhibitory effect Effects 0.000 claims description 19
- 239000004480 active ingredient Substances 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 18
- 210000004881 tumor cell Anatomy 0.000 claims description 15
- 239000012472 biological sample Substances 0.000 claims description 14
- 230000035755 proliferation Effects 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 230000002519 immonomodulatory effect Effects 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 7
- 231100000433 cytotoxic Toxicity 0.000 claims description 7
- 230000001472 cytotoxic effect Effects 0.000 claims description 7
- 230000005012 migration Effects 0.000 claims description 7
- 238000013508 migration Methods 0.000 claims description 7
- 210000000822 natural killer cell Anatomy 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 6
- 238000002512 chemotherapy Methods 0.000 claims description 5
- 230000004850 protein–protein interaction Effects 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 238000001574 biopsy Methods 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 230000002018 overexpression Effects 0.000 claims description 4
- 102000019034 Chemokines Human genes 0.000 claims description 3
- 108010012236 Chemokines Proteins 0.000 claims description 3
- 101710112752 Cytotoxin Proteins 0.000 claims description 3
- 102000014150 Interferons Human genes 0.000 claims description 3
- 108010050904 Interferons Proteins 0.000 claims description 3
- 238000011394 anticancer treatment Methods 0.000 claims description 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 3
- 239000002619 cytotoxin Substances 0.000 claims description 3
- 238000003384 imaging method Methods 0.000 claims description 3
- 229940079322 interferon Drugs 0.000 claims description 3
- 230000000861 pro-apoptotic effect Effects 0.000 claims description 3
- 230000002285 radioactive effect Effects 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 206010004593 Bile duct cancer Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 206010073069 Hepatic cancer Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 230000000977 initiatory effect Effects 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 210000000066 myeloid cell Anatomy 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 claims 2
- 230000016178 immune complex formation Effects 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 1
- 102100033471 Cbp/p300-interacting transactivator 2 Human genes 0.000 description 40
- 101000944098 Homo sapiens Cbp/p300-interacting transactivator 2 Proteins 0.000 description 40
- 101001019057 Homo sapiens Homeobox protein Meis2 Proteins 0.000 description 40
- 241000282414 Homo sapiens Species 0.000 description 33
- 239000000203 mixture Substances 0.000 description 24
- 239000012634 fragment Substances 0.000 description 21
- 230000000694 effects Effects 0.000 description 16
- 238000002347 injection Methods 0.000 description 16
- 239000007924 injection Substances 0.000 description 16
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 14
- 230000027455 binding Effects 0.000 description 14
- 230000000903 blocking effect Effects 0.000 description 13
- 230000007170 pathology Effects 0.000 description 11
- 108060003951 Immunoglobulin Proteins 0.000 description 10
- 102000018358 immunoglobulin Human genes 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 238000011534 incubation Methods 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000012636 effector Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 5
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 101001043827 Mus musculus Interleukin-2 Proteins 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 102000057297 Pepsin A Human genes 0.000 description 5
- 108090000284 Pepsin A Proteins 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000009545 invasion Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 102100025470 Carcinoembryonic antigen-related cell adhesion molecule 8 Human genes 0.000 description 4
- 101000914320 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 8 Proteins 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- -1 or other enzymatic Substances 0.000 description 4
- 229940111202 pepsin Drugs 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 101000981093 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 1 Proteins 0.000 description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000003127 anti-melanomic effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 238000002784 cytotoxicity assay Methods 0.000 description 3
- 231100000263 cytotoxicity test Toxicity 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 238000007807 Matrigel invasion assay Methods 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 210000005168 endometrial cell Anatomy 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 108091006047 fluorescent proteins Proteins 0.000 description 2
- 102000034287 fluorescent proteins Human genes 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000009650 gentamicin protection assay Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000012642 immune effector Substances 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 208000021039 metastatic melanoma Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000003396 thiol group Chemical class [H]S* 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000000529 Costimulatory and Inhibitory T-Cell Receptors Human genes 0.000 description 1
- 108010041504 Costimulatory and Inhibitory T-Cell Receptors Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101001034843 Mus musculus Interferon-induced transmembrane protein 1 Proteins 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 102000002001 Non-Receptor Type 6 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 108010015793 Non-Receptor Type 6 Protein Tyrosine Phosphatase Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010034016 Paronychia Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000005025 intestinal intraepithelial lymphocyte Anatomy 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000012977 invasive surgical procedure Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000012514 protein characterization Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 210000004879 pulmonary tissue Anatomy 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57473—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen, i.e. CEA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
Definitions
- the present invention in some embodiments thereof, relates to anti-CEACAM1 antibodies, hybridoma cells producing same and methods of using same.
- the transmembrane protein CEACAM1 [also known as biliary glycoprotein (BGP), CD66a and C-CAM1] is a member of the carcinoembryonic antigen family (CEA) that also belongs to the immunoglobulin superfamily CEACAM1 interacts with other known CD66 proteins, including CD66a, CD66c, and CD66e proteins. It is expressed on a wide spectrum of cells, ranging from epithelial cells to those of hemopoietic origin (e.g. immune cells).
- CEACAM1 has been attributed to many different functions. It was shown that the CEACAM1 protein exhibits anti-proliferative properties in carcinomas of colon, prostate, as well as other types of cancer. Additional data support the central involvement of CEACAM1 in angiogenesis and metastasis. CEACAM1 also plays a role in the modulation of innate and adaptive immune responses. For example, CEACAM1 was shown to be an inhibitory receptor for activated T cells contained within the human intestinal epithelium [see WO99/52552 and Morales et al. J. Immunol. 163 (1999), 1363-1370]. Additional reports have indicated that CEACAM1 engagement either by TCR cross-linking with mAb or by Neisseria gonorrhoeae Opa proteins inhibits T cell activation and proliferation.
- Melanoma is a malignancy of pigment-producing cells (melanocytes), responsible for 75% of skin cancer-related incidence worldwide, mainly due to extensive metastasis. Metastatic melanoma (MM) responds feebly to most anticancer regimens and overall survival mean for patients with MM is 8.5 months.
- CEACAM1 is rarely expressed by normal melanocytes, but frequently found on melanoma cells.
- CEACAM1 expression on primary cutaneous melanoma lesions strongly predicts the development of metastatic disease with poor prognosis.
- increased CEACAM1 expression was observed on NK cells derived from some patients with metastatic melanoma compared with healthy donors.
- WO2007/063424 and U.S. Patent Application No. 20070110668 disclose methods for regulating the immune system, and in particular methods for the regulation of a specific immune response, including the regulation of lymphocyte activity. These methods comprise both the negative and positive modulation of CEACAM1 protein function.
- U.S. Patent Application No. 20070071758 discloses methods and compositions for the treatment and diagnosis of cancers. Specifically, U.S. Patent Application No. 20070071758 teaches methods and compositions for enhancing the efficacy of tumor-infiltrating lymphocyte (TIL) therapy in the treatment of cancer by negatively modulating the activity of the CEACAM1 protein, such as for example, by using an immunoglobulin specific for CEACAM1.
- TIL tumor-infiltrating lymphocyte
- U.S. Patent Application No. 20080108140 discloses methods of modulating specific immune responses to create a protective immunity in the treatment of autoimmune diseases and diseases requiring the transplantation of tissue.
- U.S. Patent Application No. 20080108140 relates to the suppression of immune responses in a targeted fashion, by increasing the functional concentration of the CEACAM1 protein in the target tissue.
- U.S. Patent Application No. 20040047858 discloses specific antibodies (i.e. 34B1, 26H7 and 5F4) which are capable of modulating T cell activity via CEACAM1 and uses thereof such as in treating immune response related diseases (e.g. graft versus host disease, autoimmune diseases, cancers etc.).
- specific antibodies i.e. 34B1, 26H7 and 5F4 which are capable of modulating T cell activity via CEACAM1 and uses thereof such as in treating immune response related diseases (e.g. graft versus host disease, autoimmune diseases, cancers etc.).
- compositions which bind T cell inhibitory receptor molecules and modulate (i.e. enhance or suppress) T cell activity (e.g. cytotoxicity and proliferation), such as biliary glycoprotein binding agents, and methods of using such compositions such as for treatment of diseases (e.g. an autoimmune disease, immunodeficiency, cancer etc.).
- diseases e.g. an autoimmune disease, immunodeficiency, cancer etc.
- 5F4 mAb Regulation of human intestinal intraepithelial lymphocyte cytolytic function by biliary glycoprotein (CD66a) [Morales V M et al., J Immunol. (1999) 163(3):1363-70].
- GM8G5 and 29H2 both available commercially from Abcam Inc. abcamdotcomdotportal.
- hybridoma cell which has been deposited under ATCC Accession Number PTA-9974.
- an isolated antibody or antibody fragment comprising an antigen recognition domain having the CDR sequences and orientation of the antibody produced from the hybridoma cell.
- a method of immunomodulation comprising contacting a CEACAM1-expressing lymphocyte with the antibody or antibody fragment.
- a method of inhibiting migration or proliferation of a CEACAM1 expressing tumor cell comprising contacting the CEACAM1 expressing tumor cell with the antibody or antibody fragment, thereby inhibiting migration or proliferation of a CEACAM1 expressing tumor cell.
- a method for diagnosing a cancer in a subject in need thereof comprising contacting a biological sample derived from the subject with the antibody or antibody fragment, wherein a complex formation beyond a predetermined threshold is indicative of the cancer in the subject.
- a method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of the antibody or antibody fragment, thereby treating the cancer in the subject.
- a method of inhibiting CEACAM1 homotypic or heterotypic protein-protein interaction comprising contacting a CEACAM1-expressing lymphocyte with the antibody or antibody fragment, thereby inhibiting CEACAM1 homotypic or heterotypic protein-protein interaction.
- a pharmaceutical composition comprising as an active ingredient the antibody or antibody fragment.
- the isolated antibody or antibody fragment is attached to a cytotoxic moiety.
- the cytotoxic moiety comprises a cytotoxin, a chemokine, a chemotherapy, a pro-apoptotic, an interferon, a radioactive moiety, or combinations thereof.
- the isolated antibody or antibody fragment is attached to an identifiable moiety.
- cells of the cancer are characterized by over expression of CEACAM1 as compared to unaffected cells.
- the method of treating cancer further comprises administering to the subject lymphocytes.
- the lymphocytes comprise T cells or NK cells.
- the CEACAM1-expressing lymphocyte is a Tumor Infiltrating Lymphocyte or NK cell.
- the CEACAM1-expressing lymphocyte is a cytotoxic T cell.
- the tumor cell comprises a melanoma tumor cell.
- the cancer is melanoma.
- FIGS. 1A-B depict the specificity of MRG1 mAb.
- FIG. 2 depicts a dose-dependent inhibition of CEACAM1 homophilic interactions by the anti-CEACAM1 mAb MRG1.
- Anti-CEACAM1 mAb was added to either BW/CEACAM1 (effector cells) or 221/CEACAM1 (target cells) in various concentrations. Following one hour incubation on ice, the reciprocal cells (221/CEACAM1 or BW/CEACAM1) were added and the secretion of mouse IL-2 was measured by ELISA. 100% is defined as the activity in the absence of any antibody. The results of one representative experiment out of four are presented, each performed in triplicates.
- FIG. 3 depicts abolishment of CEACAM1-inhibitory function.
- MRG1 mAb was pre-incubated with target cells (depicted in grey) or with effector cells (depicted in white). Cells incubated without the addition of the mAb are depicted in black.
- the melanoma lines indicated (526mel, 624mel or 09mel) were used as target cells.
- TIL014 cells were used as effector cells in an E:T ratio of 10:1. Following one hour incubation on ice, the reciprocal cells were added and co-incubated for 5 hours at 37° C.
- Target cells were pre-labeled with green fluorescent dye (CFSE) and specific lysis was determined by Propidium Iodide (PI) co-staining in flow cytometry. Spontaneous death was subtracted. Assay was performed in triplicates.
- CFSE green fluorescent dye
- FIG. 4 depicts blocking of melanoma invasion by MRG1 mAbs.
- Melanoma cells (08mel or 09mel) were pre-incubated in the absence or presence of 1 ⁇ g/ml MRG1 mAb and then tested by Matrigel invasion assays. Invasion was allowed for 24 hours and the amount of invading cells was quantified with standardized XTT.
- FIG. 5 depicts blocking of net proliferation of melanoma cells by MRG1 mAbs. 526mel melanoma cells were incubated with the indicated doses (0.5 ⁇ g, 1 ⁇ g or 3 ⁇ g) of MRG1 mAbs and proliferation was monitored 2 days or 5 days following treatment.
- FIGS. 6A-B depict inhibition of human tumor growth in vivo in SCID mice by systemic injections of MRG1 as compared to PBS. Experiments were performed in two setups as follows: FIG. 6A : simultaneous injections of the antibody (0.5 mg/mouse intraperitoneally) and inoculation of cancer cells (5,000,000 cells subcutaneously); FIG. 6B : treatment of tumors generated in SCID mice (tumor volume of 75 mm 3 ) by injections of MRG1 antibody (as indicated above).
- FIG. 7 depicts enhanced efficacy in inhibition of tumor growth by a combination of MRG1 with intravenous administration of human reactive TIL as compared to intravenous TIL only.
- FIG. 8 depicts the superior effect of MRG1 mAb over previously described anti-CEACAM1 monoclonal antibodies, as well as commercially available rabbit polyclonal antibody targeting human CEACAM1 (DAKO, Glostrup Denmark), as determined by functional blocking assay.
- Various anti-CEACAM1 antibodies were tested for blocking of CEACAM1 activity, as reported by mIL-2 secretion. 100% was defined as activity in the absence of any antibody. The results of one representative experiment out of three are presented, each performed in triplicates.
- the present invention in some embodiments thereof, relates to anti CEACAM1 monoclonal antibody and hybridoma cells producing same as well as methods of using the antibody in immunomodulation and cancer treatment.
- the present inventor has produced through laborious experimentation and screening a monoclonal antibody selective for CEACAM1. This antibody was shown to be superior to other anti CEACAM1 monoclonal antibodies as demonstrated by functional blocking assays.
- the MRG1 antibody produced according to the present teachings is selective to CEACAM1 and does not cross react with other members of the CEACAM family (i.e., CEACAM 5, 6 and 8, see Example 2).
- the antibody inhibits CEACAM1 homophilic interactions, as determined by co-incubation of immune effector cells and target melanoma cells and assaying IL-2 secretion and cell lysis (see Example 3).
- the antibody was shown effective in inhibiting melanoma cells invasion and proliferation.
- in vivo administration of the antibody either alone or in combination with reactive lymphocytes was shown effective in inhibiting growth of melanoma tumors.
- hybridoma cell which has been deposited at the American Type Culture Collection (ATCC), 10801 University Boulevard., Manassas, Va., 20110-2209, United States of America, under ATCC Accession Number PTA-9974, on Apr. 29, 2009.
- ATCC American Type Culture Collection
- an isolated antibody or antibody fragment comprising an antigen recognition domain having the CDR segments and orientation of the antibody produced from the hybridoma cell, described above.
- the antibody of the present teachings is capable of binding CEACAM1 with a minimal affinity of 10 ⁇ 6 , 10 ⁇ 7 , 10 ⁇ 8 , 10 ⁇ 9 M.
- CEACAM1 refers to the protein product of the CEACAM1 gene e.g., NP_001020083.1, NP_001703.2.
- antibody as used in this invention includes intact molecules as well as functional fragments thereof, such as Fab, F(ab′)2, and Fv that are capable of binding to macrophages. According to an exemplary embodiment the antibody is a monoclonal antibody such as termed herein, MRG1.
- Functional antibody fragments are defined as follows: (1) Fab, the fragment which contains a monovalent antigen-binding fragment of an antibody molecule, can be produced by digestion of whole antibody with the enzyme papain to yield an intact light chain and a portion of one heavy chain; (2) Fab′, the fragment of an antibody molecule that can be obtained by treating whole antibody with pepsin, followed by reduction, to yield an intact light chain and a portion of the heavy chain; two Fab′ fragments are obtained per antibody molecule; (3) (Fab′)2, the fragment of the antibody that can be obtained by treating whole antibody with the enzyme pepsin without subsequent reduction; F(ab′)2 is a dimer of two Fab′ fragments held together by two disulfide bonds; (4) Fv, defined as a genetically engineered fragment containing the variable region of the light chain and the variable region of the heavy chain expressed as two chains; and (5) Single chain antibody (“SCA”), a genetically engineered molecule containing the variable region of the light chain and the variable region of the heavy chain, linked by
- the antibody of the present invention has the same complementarity determining regions (CDR) orientation as that of the antibody produced by hybridoma cell, having the deposit details as described above. That is CDR1, CDR2, CDR3 are placed in the same orientation on V H and V L chains.
- CDR1 complementarity determining regions
- Antibody fragments according to the present invention can be prepared by proteolytic hydrolysis of the antibody or by expression in E. coli or mammalian cells (e.g. Chinese hamster ovary cell culture or other protein expression systems) of DNA encoding the fragment.
- Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods.
- antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted F(ab′)2.
- This fragment can be further cleaved using a thiol reducing agent, and optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages, to produce 3.5S Fab′ monovalent fragments.
- a thiol reducing agent optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages
- an enzymatic cleavage using pepsin produces two monovalent Fab′ fragments and an Fc fragment directly.
- cleaving antibodies such as separation of heavy chains to form monovalent light-heavy chain fragments, further cleavage of fragments, or other enzymatic, chemical, or genetic techniques may also be used, so long as the fragments bind to the antigen that is recognized by the intact antibody.
- Fv fragments comprise an association of VH and VL chains. This association may be noncovalent, as described in Inbar et al. [Proc. Nat'l Acad. Sci. USA 69:2659-62 (19720]. Alternatively, the variable chains can be linked by an intermolecular disulfide bond or cross-linked by chemicals such as glutaraldehyde. Preferably, the Fv fragments comprise VH and VL chains connected by a peptide linker.
- sFv single-chain antigen binding proteins
- the structural gene is inserted into an expression vector, which is subsequently introduced into a host cell such as E. coli .
- the recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging the two V domains.
- Methods for producing sFvs are described, for example, by [Whitlow and Filpula, Methods 2: 97-105 (1991); Bird et al., Science 242:423-426 (1988); Pack et al., Bio/Technology 11:1271-77 (1993); and U.S. Pat. No. 4,946,778, which is hereby incorporated by reference in its entirety.
- CDR peptides (“minimal recognition units”) can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody-producing cells. See, for example, Larrick and Fry [Methods, 2: 106-10 (1991)]. According to some embodiments of the present invention, the CDRs can be implemented in any form of an antibody such as by the use of recombinant DNA technology.
- Humanized forms of non-human (e.g., murine) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab′, F(ab′).sub.2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin.
- Humanized antibodies include human immunoglobulins (recipient antibody) in which residues form a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity.
- CDR complementary determining region
- donor antibody such as mouse, rat or rabbit having the desired specificity, affinity and capacity.
- Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues.
- Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences.
- the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence.
- the humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)].
- Fc immunoglobulin constant region
- a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as import residues, which are typically taken from an import variable domain. Humanization can be essentially performed following the method of Winter and co-workers [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody.
- humanized antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species.
- humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.
- Human antibodies can also be produced using various techniques known in the art, including phage display libraries [Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)].
- the techniques of Cole et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985) and Boerner et al., J. Immunol., 147(1):86-95 (1991)1.
- human antibodies can be made by introduction of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Pat. Nos.
- the antibody is attached to a cytotoxic moiety.
- the antibody is attached to an identifiable moiety.
- the identifiable moiety can be a member of a binding pair, which is identifiable via its interaction with an additional member of the binding pair and a label which is directly visualized.
- the member of the binding pair is an antigen which is identified by a corresponding labeled antibody.
- the label is a fluorescent protein or an enzyme producing a colorimetric reaction.
- the cytotoxic or therapeutic moiety can be, for example, a cytotoxic moiety, a toxic moiety, a cytokine moiety, a bi-specific antibody moiety, a cytotoxin, a chemokine, a chemotherapy, a pro-apoptotic, interferon, a radioactive moiety, or combinations thereof, examples of which are provided infra.
- the antibody of the present invention can decrease the inhibitory CEACAM1 homophilic (or homotypic) or heterotypic interactions to thereby augment the activity of lymphocytes.
- CEACAM1 homophilic interactions occur through the N-domain.
- Several amino acids are crucial for this interaction, including R43, Q44, D64 and R82.
- the interaction causes phosphorylation of a cytoplasmic tyrosine residue that recruits SHP-1 phosphatase. This initiates an inhibitory cascade within the lymphocytes, which targets proximal mediators, such as ZAP70.
- the antibody of the present invention can be used to block CEACAM1 on either or both immune effector cells (CEACAM1 expressing lymphocytes e.g., tumor infiltrating cells, T cells or NK cells) and target cells (e.g., CEACAM1 expressing pathological cells such as cancer cells).
- immune effector cells CEACAM1 expressing lymphocytes e.g., tumor infiltrating cells, T cells or NK cells
- target cells e.g., CEACAM1 expressing pathological cells such as cancer cells.
- cancer cells which are candidates for this therapy include, but are not limited to, melanoma, lung, thyroid, breast, colon, prostate, hepatic, bladder, renal, cervical, pancreatic, leukemia, lymphoma, myeloid, ovarian, uterus, sarcoma, biliary, or endometrial cells.
- the present invention also contemplates isolated antibodies or antibody fragments that compete for binding to CEACAM1 with the antibodies produced by the above-described hybridoma cell.
- Those antibodies may be humanized, xenogeneic, or chimeric antibodies (as described in detail above) being suitable for e.g. therapeutic applications.
- An antibody fragment of the antibody can be, for example, a single chain Fv fragment, an F(ab′) fragment, an F(ab) fragment, and an F(ab′)2 fragment.
- a method of rendering a CEACAM1 expressing tumor cell susceptible to immunomodulation comprising contacting the CEACAM1 expressing tumor cell (e.g., melanoma, lung, thyroid, breast, colon, prostate, hepatic, bladder, renal, cervical, pancreatic, leukemia, lymphoma, myeloid, ovarian, uterus, sarcoma, biliary or endometrial cell) with the antibody or antibody fragment described above, thereby rendering the CEACAM1 expressing tumor cell susceptible to immunomodulation.
- the CEACAM1 expressing tumor cell e.g., melanoma, lung, thyroid, breast, colon, prostate, hepatic, bladder, renal, cervical, pancreatic, leukemia, lymphoma, myeloid, ovarian, uterus, sarcoma, biliary or endometrial cell
- immunomodulation refers to lymphocyte dependent immunomodulation (e.g., by NK cells or tumor infiltrating lymphocytes).
- the present invention also envisages a method of immunomodulation (e.g., inhibiting CEACAM1 homotypic or heterotypic protein-protein interaction), by contacting a CEACAM1-expressing lymphocyte with the antibody or antibody fragment described herein.
- a method of immunomodulation e.g., inhibiting CEACAM1 homotypic or heterotypic protein-protein interaction
- the methods of the present teachings can be effected in-vitro, ex-vivo (e.g., used in T cell based adoptive immunotherapy) or in-vivo.
- antibodies of some embodiments of the invention can have anti cancer activity which is independent from its immunomodulatory activity described above.
- the present teachings further provide for a method of inhibiting migration or proliferation of a CEACAM1 expressing tumor cell, the method comprising contacting the CEACAM1 expressing tumor cell with the antibody or antibody fragment described herein, thereby inhibiting migration or proliferation of a CEACAM1 expressing tumor cell.
- inhibiting refers to at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% 100% inhibition in proliferation or migration which can be assayed using methods which are well known in the art (see examples section below).
- Antibodies of the present invention can be effectively used for the treatment of cancer.
- a method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of the antibody or antibody fragment described herein, thereby treating the cancer in the subject.
- cancer which can be diagnosed or treated according to the present teachings include, but are not limited to, melanoma, sarcoma, lung cancer, cancer of the thyroid, breast cancer, colon cancer, prostate cancer, hepatic cancer, bladder cancer, renal cancer, cervical cancer, pancreatic cancer, leukemia, lymphoma, myeloid cell related cancer, ovarian cancer, uterus cancer, biliary cancer or endometrial cancer.
- the cancer is melanoma.
- treating refers to inhibiting, preventing or arresting the development of a pathology (disease, disorder or condition) and/or causing the reduction, remission, or regression of a pathology.
- pathology disease, disorder or condition
- Those of skill in the art will understand that various methodologies and assays can be used to assess the development of a pathology, and similarly, various methodologies and assays may be used to assess the reduction, remission or regression of a pathology.
- the term “preventing” refers to keeping a disease, disorder or condition from occurring in a subject who may be at risk for the disease, but has not yet been diagnosed as having the disease.
- the term “subject” includes mammals, preferably human beings at any age which suffer from the pathology. Preferably, this term encompasses individuals who are at risk to develop the pathology.
- lymphocytes such as T cells (e.g. Tumor Infiltrating Lymphocytes) or NK cells may be administered to the subject prior to, concomitantly with or following administration of the antibody or antibody fragment of the present invention.
- lymphocytes may be obtained from the subject (e.g. from the peripheral blood or from the tumor of same) or from a donor (an allogeneic or a syngeneic lymphocyte donor), treated by ex-vivo expansion methods as to obtained viable lymphocytes [e.g.
- the subject may be treated by any other anti-cancer treatment (e.g. chemotherapy, radiation therapy, etc.) prior to administration of the antibody or antibody fragment or prior to administration of the lymphocytes.
- any other anti-cancer treatment e.g. chemotherapy, radiation therapy, etc.
- the antibody of the present invention can be administered to an organism per se, or in a pharmaceutical composition where it is mixed with suitable carriers or excipients.
- a “pharmaceutical composition” refers to a preparation of one or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and excipients.
- the purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.
- active ingredient refers to the antibody accountable for the biological effect.
- physiologically acceptable carrier and “pharmaceutically acceptable carrier” which may be interchangeably used refer to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.
- An adjuvant is included under these phrases.
- excipient refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient.
- excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.
- Suitable routes of administration may, for example, include oral, rectal, transmucosal, especially transnasal, intestinal or parenteral delivery, including intramuscular, subcutaneous and intramedullary injections as well as intrathecal, direct intraventricular, intracardiac, e.g., into the right or left ventricular cavity, into the common coronary artery, intravenous, inrtaperitoneal, intranasal, or intraocular injections.
- neurosurgical strategies e.g., intracerebral injection or intracerebroventricular infusion
- molecular manipulation of the agent e.g., production of a chimeric fusion protein that comprises a transport peptide that has an affinity for an endothelial cell surface molecule in combination with an agent that is itself incapable of crossing the BBB
- pharmacological strategies designed to increase the lipid solubility of an agent (e.g., conjugation of water-soluble agents to lipid or cholesterol carriers)
- the transitory disruption of the integrity of the BBB by hyperosmotic disruption resulting from the infusion of a mannitol solution into the carotid artery or the use of a biologically active agent such as an angiotensin peptide).
- each of these strategies has limitations, such as the inherent risks associated with an invasive surgical procedure, a size limitation imposed by a limitation inherent in the endogenous transport systems, potentially undesirable biological side effects associated with the systemic administration of a chimeric molecule comprised of a carrier motif that could be active outside of the CNS, and the possible risk of brain damage within regions of the brain where the BBB is disrupted, which renders it a suboptimal delivery method.
- tissue refers to part of an organism consisting of an aggregate of cells having a similar structure and/or a common function. Examples include, but are not limited to, brain tissue, retina, skin tissue, hepatic tissue, pancreatic tissue, bone, cartilage, connective tissue, blood tissue, muscle tissue, cardiac tissue brain tissue, vascular tissue, renal tissue, pulmonary tissue, gonadal tissue, hematopoietic tissue.
- compositions of the present invention may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
- compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active ingredients into preparations which, can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
- the active ingredients of the pharmaceutical composition may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological salt buffer.
- physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological salt buffer.
- penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
- the pharmaceutical composition can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art.
- Such carriers enable the pharmaceutical composition to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for oral ingestion by a patient.
- Pharmacological preparations for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries if desired, to obtain tablets or dragee cores.
- Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carbomethylcellulose; and/or physiologically acceptable polymers such as polyvinylpyrrolidone (PVP).
- disintegrating agents may be added, such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
- Dragee cores are provided with suitable coatings.
- suitable coatings For this purpose, concentrated sugar solutions may be used which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures.
- Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
- compositions which can be used orally include push-fit capsules made of gelatin as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
- the push-fit capsules may contain the active ingredients in admixture with filler such as lactose, binders such as starches, lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- the active ingredients may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
- stabilizers may be added. All formulations for oral administration should be in dosages suitable for the chosen route of administration.
- compositions may take the form of tablets or lozenges formulated in conventional manner.
- the active ingredients for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from a pressurized pack or a nebulizer with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane or carbon dioxide.
- a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane or carbon dioxide.
- the dosage unit may be determined by providing a valve to deliver a metered amount.
- Capsules and cartridges of, e.g., gelatin for use in a dispenser may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
- compositions described herein may be formulated for parenteral administration, e.g., by bolus injection or continuos infusion.
- Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multidose containers with optionally, an added preservative.
- the compositions may be suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- compositions for parenteral administration include aqueous solutions of the active preparation in water-soluble form. Additionally, suspensions of the active ingredients may be prepared as appropriate oily or water based injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acids esters such as ethyl oleate, triglycerides or liposomes. Aqueous injection suspensions may contain substances, which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the active ingredients to allow for the preparation of highly concentrated solutions.
- the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water based solution, before use.
- a suitable vehicle e.g., sterile, pyrogen-free water based solution
- compositions of the present invention may also be formulated in rectal compositions such as suppositories or retention enemas, using, e.g., conventional suppository bases such as cocoa butter or other glycerides.
- compositions suitable for use in context of the present invention include compositions wherein the active ingredients are contained in an amount effective to achieve the intended purpose. More specifically, a therapeutically effective amount means an amount of active ingredients effective to prevent, alleviate or ameliorate symptoms of a disorder (e.g., cancer) or prolong the survival of the subject being treated.
- a disorder e.g., cancer
- the therapeutically effective amount or dose can be estimated initially from in vitro and cell culture assays.
- a dose can be formulated in animal models to achieve a desired concentration or titer. Such information can be used to more accurately determine useful doses in humans.
- Toxicity and therapeutic efficacy of the active ingredients described herein can be determined by standard pharmaceutical procedures in vitro, in cell cultures or experimental animals.
- the data obtained from these in vitro and cell culture assays and animal studies can be used in formulating a range of dosage for use in human.
- the dosage may vary depending upon the dosage form employed and the route of administration utilized.
- the exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g., Fingl, et al., 1975, in “The Pharmacological Basis of Therapeutics”, Ch. 1 p.1).
- Dosage amount and interval may be adjusted individually to provide antibody levels of the active ingredient are sufficient to induce or suppress the biological effect (minimal effective concentration, MEC).
- MEC minimum effective concentration
- the MEC will vary for each preparation, but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. Detection assays can be used to determine plasma concentrations.
- Therapeutic efficacy can be further validated in correlative animal models which are well known in the art.
- dosing can be of a single or a plurality of administrations, with course of treatment lasting from several days to several weeks or until cure is effected or diminution of the disease state is achieved.
- compositions to be administered will, of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, etc.
- compositions of the present invention may, if desired, be presented in a pack or dispenser device, such as an FDA approved kit, which may contain one or more unit dosage forms containing the active ingredient.
- the pack may, for example, comprise metal or plastic foil, such as a blister pack.
- the pack or dispenser device may be accompanied by instructions for administration.
- the pack or dispenser may also be accommodated by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or human or veterinary administration. Such notice, for example, may be of labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert.
- Compositions comprising a preparation of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition, as is further detailed above.
- antibodies of the present invention can also be used in diagnostic applications.
- a method for diagnosing a cancer in a subject in need thereof comprising contacting a biological sample derived from the subject (in-vivo or ex-vivo) with the antibody or antibody fragment described herein, wherein a complex formation beyond a predetermined threshold is indicative of the cancer in the subject.
- cells of the cancer are characterized by over expression of CEACAM1 as compared to unaffected cells.
- the method of the invention is effected under conditions sufficient to form an immunocomplex; such conditions (e.g., appropriate concentrations, buffers, temperatures, reaction times) as well as methods to optimize such conditions are known to those skilled in the art, and examples are disclosed herein.
- immunocomplex refers to a complex which comprises the antibody of the invention and the CEACAM1.
- Determining a presence or level of the immunocomplex of the invention may be direct or by detecting an identifiable (detectable) moiety which may be attached to the antibody.
- the level of the immunocomplex in the tested cell (e.g., a cell of a subject in need thereof) is compared to a predetermined threshold.
- a predetermined threshold may be determined based on a known reference level and/or a level in a control cell or serum.
- the control cell can be obtained from a control, healthy subject (e.g., a subject not suffering from the cancer) or from the same subject prior to disease initiation or following treatment.
- the control subject is of the same species e.g. human, preferably matched with the same age, weight, sex etc. as the subject in need thereof.
- diagnosis refers to determining presence or absence of a pathology, classifying a pathology or a symptom, determining a severity of the pathology, monitoring pathology progression, forecasting an outcome of a pathology and/or prospects of recovery.
- composition or method may include additional ingredients and/or steps, but only if the additional ingredients and/or steps do not materially alter the basic and novel characteristics of the claimed composition or method.
- a compound or “at least one compound” may include a plurality of compounds, including mixtures thereof.
- range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
- a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range.
- the phrases “ranging/ranges between” a first indicate number and a second indicate number and “ranging/ranges from” a first indicate number “to” a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.
- method refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.
- mice were immunized 3 times, at 2 week intervals, with 5 micrograms of recombinant human CEACAM1 (entire protein, commercially available from R&D Systems). Splenocytes were harvested and fused with SP2/0 cells, to generate a hybridoma library.
- the hybridoma producing the CEACAM1-blocking antibody was re-cloned several times to yield a stable clone.
- Kat4c mAb and rabbit polyclonal anti-CEACAM were purchased from DAKO (Glostrup, Denmark).
- CEACAM-negative 721.221 human cells (parental B cells) were stably transfected with CEACAM1, CEACAM5, CEACAM6 or CEACAM8 by electroporation and selection with G418.
- the murine thymoma BW parental cells (cells that lack TCR alpha and beta chains, yet retain full secretion machinery of IL-2) were transfected with a chimeric molecule comprising the extracellular portion of human CEACAM1 fused to the transmembrane and cytosolic tail of murine zeta chain. Transfection was performed by electroporation and selection with G418.
- Hybridomas were screened for CEACAM1 binding activity by flow cytometry as follows:
- FIG. 1A the MRG1 mAb generated according to the present teachings is specific to human CEACAM1. It has an insignificant cross-reactivity to CEACAM5 and no binding to CEACAM6 or CEACAM8.
- FIG. 1B shows that all transfectants expressed CEACAM molecules, with CEACAM1 being the lowest, which emphasizes the specificity pattern of MRG1.
- the mAb is Capable of Inhibiting CEACAM1 Homophilic Binding
- CEACAM1 blocking activity was tested using a BW functional system.
- the BW functional system comprises a mouse cell line (BW) stably transfected with a chimeric molecule comprising the extracellular domain of human CEACAM1 fused to mouse zeta chain (BW/CEACAM1-zeta, see Example 2, above).
- BW/CEACAM1-zeta mouse zeta chain
- Co-incubation of the BW/CEACAM1-zeta cells with other CEACAM1-positive cells resulted in the secretion of measurable concentrations of mouse IL-2.
- BW/CEACAM1-zeta effector cells
- 221/CEACAM1 target cells
- MRG1 mAb 10-40 ng/ml MRG1 mAb.
- the reciprocal cells (221/CEACAM1 or BW/CEACAM1) were added and the secretion of mouse IL-2 was measured by sandwich ELISA (R&D systems).
- Cytotoxicity assays testing the killing of various melanoma lines by tumor infiltrating lymphocytes was performed in the presence or absence of 1 ⁇ g/ml MRG1 mAb.
- CEACAM1 High 526 mel, 624mel and CEACAM1 dim 09 mel melanoma cells were used as target cells.
- TIL014 cells were used as effector cells at an E:T ratio of 10:1.
- Target cells were pre-labeled with a green fluorescent dye (CFSE) and specific lysis was determined by Propidium Iodide (PI) co-staining in flow cytometry. Spontaneous death was subtracted.
- CFSE green fluorescent dye
- the purified MRG1 mAb MRG1 showed a dose-dependant inhibition of CEACAM1 homophilic binding.
- the mAb efficiently reduced CEACAM1 interactions, effectively reaching a plateau at a concentration of 20 ng/ml.
- the two experimental settings i.e. the addition of MRG1 mAb to the effector cells, BW/CEACAM1-zeta, or to the target cells, 221/CEACAM1, showed similar results (secretion of the mouse IL-2 was effectively blocked).
- MRG1 mAb The blocking effect of MRG1 mAb was further demonstrated in cytotoxicity assays. As shown if FIG. 3 , killing of the CEACAM1 high 526 mel and 624mel cells was enhanced by incubation of the antibody with effector cells (but not on target cells). The killing of the CEACAM1 thm 09 mel cells was unaffected by the presence of MRG1 mAb ( FIG. 3 ).
- melanoma cells (08mel or 09mel) were pre-incubated in the presence or absence of 1 ⁇ g/ml MRG1 mAb and then tested by Matrigel invasion assays. Invasion was allowed for 24 hours and the amount of invading cells was quantified with standardized XTT.
- CEACAM1 High 526 mel cells were seeded on day 0 in 48-well plates (2,500 cells per well). On seeding, MRG1 was added in 3 different concentrations (0.5, 1, or 3 ⁇ g/ml), or not added at all. Total viable cells were counted 2 days or 5 days after seeding. Proliferation was determined with standardized XTT and by direct cell counting.
- MRG1 blocked the invasion of CEACAM1-positive 08mel cells (CEACAM1 expression level was medium, i.e. median fluorescence intensity of CEACAM1 expression was 50) and had little or no effect on CEACAM1dim 09mel cells (CEACAM1 expression level was low, i.e. median fluorescence intensity of CEACAM1 expression was 15).
- MRG1 was also tested in net proliferation assays. A dose-dependent inhibition in net proliferation of 526mel cells was observed ( FIG. 5 ). Following 5 days of treatment, proliferation was reduced by more than 60% (with 3 ⁇ g MRG1 mAb).
- CEACAM1 + human melanoma cells were injected subcutaneously to the flank of 7 week old SCID-NOD mice. Tumor masses formed in 100% of the mice within 14-17 days and continued to grow. Tumor dimensions were monitored non-invasively with a caliper 3 times a week and volume approximation was calculated as (d1 ⁇ d2 ⁇ d3/2).
- MRG1 Administration of MRG1 was performed by injection of 0.5 mg antibody diluted in 0.5 ml sterile PBS intraperitoneally. Injection of PBS served as control.
- MRG1 is Superior to Previously Described Anti-CEACAM1 Antibodies
- CEACAM1 blocking activity was tested using a BW functional system as described in detail in Example 3, hereinabove.
- Example 3 the inventors demonstrated a nearly complete blocking of CEACAM1 activity using 15 ng/ml MRG1 mAb.
- the anti-CEACAM1 monoclonal antibody Kat4c was able to yield a minor blocking effect only when 200-fold higher concentrations were tested and the polyclonal rabbit anti-CEACAM antibody yielded a similar inhibitory effect with 40-fold higher concentration (2600 ng/ml and 600 ng/ml, respectively, FIG. 8 ).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
A hybridoma cell which has been deposited under ATCC Accession Number PTA-9974 is disclosed. Also provided are Antibodies and methods of using same.
Description
- This application is a continuation of U.S. patent application Ser. No. 14/990,959 filed Jan. 8, 2016, which is a divisional of U.S. patent application Ser. No. 14/061,277, filed Oct. 23, 2013, now U.S. Pat. No. 9,261,501, issued Feb. 16, 2016, which is a continuation of U.S. patent application Ser. No. 13/318,266, filed on Dec. 21, 2011, now U.S. Pat. No. 8,598,322, issued Dec. 3, 2013, which is a 35 U.S.C. §371 National Phase Entry Application from PCT/IL2010/000348, filed Apr. 29, 2010, and designating the United States, which claims the benefit of U.S. Provisional Application No. 61/213,040, filed on Apr. 30, 2009, which are incorporated herein in their entireties.
- The present invention, in some embodiments thereof, relates to anti-CEACAM1 antibodies, hybridoma cells producing same and methods of using same.
- The transmembrane protein CEACAM1 [also known as biliary glycoprotein (BGP), CD66a and C-CAM1] is a member of the carcinoembryonic antigen family (CEA) that also belongs to the immunoglobulin superfamily CEACAM1 interacts with other known CD66 proteins, including CD66a, CD66c, and CD66e proteins. It is expressed on a wide spectrum of cells, ranging from epithelial cells to those of hemopoietic origin (e.g. immune cells).
- Many different functions have been attributed to the CEACAM1 protein. It was shown that the CEACAM1 protein exhibits anti-proliferative properties in carcinomas of colon, prostate, as well as other types of cancer. Additional data support the central involvement of CEACAM1 in angiogenesis and metastasis. CEACAM1 also plays a role in the modulation of innate and adaptive immune responses. For example, CEACAM1 was shown to be an inhibitory receptor for activated T cells contained within the human intestinal epithelium [see WO99/52552 and Morales et al. J. Immunol. 163 (1999), 1363-1370]. Additional reports have indicated that CEACAM1 engagement either by TCR cross-linking with mAb or by Neisseria gonorrhoeae Opa proteins inhibits T cell activation and proliferation.
- Melanoma is a malignancy of pigment-producing cells (melanocytes), responsible for 75% of skin cancer-related incidence worldwide, mainly due to extensive metastasis. Metastatic melanoma (MM) responds feebly to most anticancer regimens and overall survival mean for patients with MM is 8.5 months. CEACAM1 is rarely expressed by normal melanocytes, but frequently found on melanoma cells. CEACAM1 expression on primary cutaneous melanoma lesions strongly predicts the development of metastatic disease with poor prognosis. Moreover, increased CEACAM1 expression was observed on NK cells derived from some patients with metastatic melanoma compared with healthy donors.
- WO2007/063424 and U.S. Patent Application No. 20070110668 disclose methods for regulating the immune system, and in particular methods for the regulation of a specific immune response, including the regulation of lymphocyte activity. These methods comprise both the negative and positive modulation of CEACAM1 protein function.
- U.S. Patent Application No. 20070071758 discloses methods and compositions for the treatment and diagnosis of cancers. Specifically, U.S. Patent Application No. 20070071758 teaches methods and compositions for enhancing the efficacy of tumor-infiltrating lymphocyte (TIL) therapy in the treatment of cancer by negatively modulating the activity of the CEACAM1 protein, such as for example, by using an immunoglobulin specific for CEACAM1.
- U.S. Patent Application No. 20080108140 discloses methods of modulating specific immune responses to create a protective immunity in the treatment of autoimmune diseases and diseases requiring the transplantation of tissue. In particular, U.S. Patent Application No. 20080108140 relates to the suppression of immune responses in a targeted fashion, by increasing the functional concentration of the CEACAM1 protein in the target tissue.
- U.S. Patent Application No. 20040047858 discloses specific antibodies (i.e. 34B1, 26H7 and 5F4) which are capable of modulating T cell activity via CEACAM1 and uses thereof such as in treating immune response related diseases (e.g. graft versus host disease, autoimmune diseases, cancers etc.).
- U.S. Patent Application Nos. 20020028203, 20050169922 and 20080102071 disclose compositions which bind T cell inhibitory receptor molecules and modulate (i.e. enhance or suppress) T cell activity (e.g. cytotoxicity and proliferation), such as biliary glycoprotein binding agents, and methods of using such compositions such as for treatment of diseases (e.g. an autoimmune disease, immunodeficiency, cancer etc.).
- 5F4 mAb: Regulation of human intestinal intraepithelial lymphocyte cytolytic function by biliary glycoprotein (CD66a) [Morales V M et al., J Immunol. (1999) 163(3):1363-70].
- GM8G5 and 29H2—both available commercially from Abcam Inc. abcamdotcomdotportal.
- According to an aspect of some embodiments of the present invention there is provided a hybridoma cell which has been deposited under ATCC Accession Number PTA-9974.
- According to an aspect of some embodiments of the present invention there is provided an isolated antibody or antibody fragment comprising an antigen recognition domain having the CDR sequences and orientation of the antibody produced from the hybridoma cell.
- According to an aspect of some embodiments of the present invention there is provided a method of immunomodulation, the method comprising contacting a CEACAM1-expressing lymphocyte with the antibody or antibody fragment.
- According to an aspect of some embodiments of the present invention there is provided a method of inhibiting migration or proliferation of a CEACAM1 expressing tumor cell, the method comprising contacting the CEACAM1 expressing tumor cell with the antibody or antibody fragment, thereby inhibiting migration or proliferation of a CEACAM1 expressing tumor cell.
- According to an aspect of some embodiments of the present invention there is provided a method for diagnosing a cancer in a subject in need thereof, the method comprising contacting a biological sample derived from the subject with the antibody or antibody fragment, wherein a complex formation beyond a predetermined threshold is indicative of the cancer in the subject.
- According to an aspect of some embodiments of the present invention there is provided a method of treating cancer, the method comprising administering to a subject in need thereof a therapeutically effective amount of the antibody or antibody fragment, thereby treating the cancer in the subject.
- According to an aspect of some embodiments of the present invention there is provided a method of inhibiting CEACAM1 homotypic or heterotypic protein-protein interaction, the method comprising contacting a CEACAM1-expressing lymphocyte with the antibody or antibody fragment, thereby inhibiting CEACAM1 homotypic or heterotypic protein-protein interaction.
- According to an aspect of some embodiments of the present invention there is provided a pharmaceutical composition comprising as an active ingredient the antibody or antibody fragment.
- According to some embodiments of the invention, the isolated antibody or antibody fragment is attached to a cytotoxic moiety.
- According to some embodiments of the invention, the cytotoxic moiety comprises a cytotoxin, a chemokine, a chemotherapy, a pro-apoptotic, an interferon, a radioactive moiety, or combinations thereof.
- According to some embodiments of the invention, the isolated antibody or antibody fragment is attached to an identifiable moiety.
- According to some embodiments of the invention, cells of the cancer are characterized by over expression of CEACAM1 as compared to unaffected cells.
- According to some embodiments of the invention, the method of treating cancer further comprises administering to the subject lymphocytes.
- According to some embodiments of the invention, the lymphocytes comprise T cells or NK cells.
- According to some embodiments of the invention, the CEACAM1-expressing lymphocyte is a Tumor Infiltrating Lymphocyte or NK cell.
- According to some embodiments of the invention, the CEACAM1-expressing lymphocyte is a cytotoxic T cell.
- According to some embodiments of the invention, the tumor cell comprises a melanoma tumor cell.
- According to some embodiments of the invention, the cancer is melanoma.
- Unless otherwise defined, all technical and/or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and/or materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.
- Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the invention. In this regard, the description taken with the drawings makes apparent to those skilled in the art how embodiments of the invention may be practiced.
- In the drawings:
-
FIGS. 1A-B depict the specificity of MRG1 mAb. 721.221 parental B cells stably transfected with CEACAM1 (green), CEACAM5 (red), CEACAM6 (purple), CEACAM8 (blue) or mock (black), were subjected to FACS analysis using the different anti-human CEACAM antibodies: MRG1 mAb (FIG. 1A ) and Kat4c mAb (FIG. 1B ). -
FIG. 2 depicts a dose-dependent inhibition of CEACAM1 homophilic interactions by the anti-CEACAM1 mAb MRG1. Anti-CEACAM1 mAb was added to either BW/CEACAM1 (effector cells) or 221/CEACAM1 (target cells) in various concentrations. Following one hour incubation on ice, the reciprocal cells (221/CEACAM1 or BW/CEACAM1) were added and the secretion of mouse IL-2 was measured by ELISA. 100% is defined as the activity in the absence of any antibody. The results of one representative experiment out of four are presented, each performed in triplicates. -
FIG. 3 depicts abolishment of CEACAM1-inhibitory function. MRG1 mAb was pre-incubated with target cells (depicted in grey) or with effector cells (depicted in white). Cells incubated without the addition of the mAb are depicted in black. The melanoma lines indicated (526mel, 624mel or 09mel) were used as target cells. TIL014 cells were used as effector cells in an E:T ratio of 10:1. Following one hour incubation on ice, the reciprocal cells were added and co-incubated for 5 hours at 37° C. Target cells were pre-labeled with green fluorescent dye (CFSE) and specific lysis was determined by Propidium Iodide (PI) co-staining in flow cytometry. Spontaneous death was subtracted. Assay was performed in triplicates. -
FIG. 4 depicts blocking of melanoma invasion by MRG1 mAbs. Melanoma cells (08mel or 09mel) were pre-incubated in the absence or presence of 1 μg/ml MRG1 mAb and then tested by Matrigel invasion assays. Invasion was allowed for 24 hours and the amount of invading cells was quantified with standardized XTT. -
FIG. 5 depicts blocking of net proliferation of melanoma cells by MRG1 mAbs. 526mel melanoma cells were incubated with the indicated doses (0.5 μg, 1 μg or 3 μg) of MRG1 mAbs and proliferation was monitored 2 days or 5 days following treatment. -
FIGS. 6A-B depict inhibition of human tumor growth in vivo in SCID mice by systemic injections of MRG1 as compared to PBS. Experiments were performed in two setups as follows:FIG. 6A : simultaneous injections of the antibody (0.5 mg/mouse intraperitoneally) and inoculation of cancer cells (5,000,000 cells subcutaneously);FIG. 6B : treatment of tumors generated in SCID mice (tumor volume of 75 mm3) by injections of MRG1 antibody (as indicated above). -
FIG. 7 depicts enhanced efficacy in inhibition of tumor growth by a combination of MRG1 with intravenous administration of human reactive TIL as compared to intravenous TIL only. -
FIG. 8 depicts the superior effect of MRG1 mAb over previously described anti-CEACAM1 monoclonal antibodies, as well as commercially available rabbit polyclonal antibody targeting human CEACAM1 (DAKO, Glostrup Denmark), as determined by functional blocking assay. Various anti-CEACAM1 antibodies were tested for blocking of CEACAM1 activity, as reported by mIL-2 secretion. 100% was defined as activity in the absence of any antibody. The results of one representative experiment out of three are presented, each performed in triplicates. - The present invention, in some embodiments thereof, relates to anti CEACAM1 monoclonal antibody and hybridoma cells producing same as well as methods of using the antibody in immunomodulation and cancer treatment.
- Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details set forth in the following description or exemplified by the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways.
- The present inventor has produced through laborious experimentation and screening a monoclonal antibody selective for CEACAM1. This antibody was shown to be superior to other anti CEACAM1 monoclonal antibodies as demonstrated by functional blocking assays.
- As is illustrated herein below, the MRG1 antibody produced according to the present teachings, is selective to CEACAM1 and does not cross react with other members of the CEACAM family (i.e.,
CEACAM - Thus according to an aspect of the invention there is provided a hybridoma cell which has been deposited at the American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, Va., 20110-2209, United States of America, under ATCC Accession Number PTA-9974, on Apr. 29, 2009.
- According to a further aspect of the invention there is provided an isolated antibody or antibody fragment comprising an antigen recognition domain having the CDR segments and orientation of the antibody produced from the hybridoma cell, described above.
- The antibody of the present teachings is capable of binding CEACAM1 with a minimal affinity of 10−6, 10−7, 10−8, 10−9 M.
- As used herein the term “CEACAM1” refers to the protein product of the CEACAM1 gene e.g., NP_001020083.1, NP_001703.2.
- The term “antibody” as used in this invention includes intact molecules as well as functional fragments thereof, such as Fab, F(ab′)2, and Fv that are capable of binding to macrophages. According to an exemplary embodiment the antibody is a monoclonal antibody such as termed herein, MRG1. Functional antibody fragments are defined as follows: (1) Fab, the fragment which contains a monovalent antigen-binding fragment of an antibody molecule, can be produced by digestion of whole antibody with the enzyme papain to yield an intact light chain and a portion of one heavy chain; (2) Fab′, the fragment of an antibody molecule that can be obtained by treating whole antibody with pepsin, followed by reduction, to yield an intact light chain and a portion of the heavy chain; two Fab′ fragments are obtained per antibody molecule; (3) (Fab′)2, the fragment of the antibody that can be obtained by treating whole antibody with the enzyme pepsin without subsequent reduction; F(ab′)2 is a dimer of two Fab′ fragments held together by two disulfide bonds; (4) Fv, defined as a genetically engineered fragment containing the variable region of the light chain and the variable region of the heavy chain expressed as two chains; and (5) Single chain antibody (“SCA”), a genetically engineered molecule containing the variable region of the light chain and the variable region of the heavy chain, linked by a suitable polypeptide linker as a genetically fused single chain molecule.
- As indicated above, the antibody of the present invention has the same complementarity determining regions (CDR) orientation as that of the antibody produced by hybridoma cell, having the deposit details as described above. That is CDR1, CDR2, CDR3 are placed in the same orientation on VH and VL chains.
- Antibody fragments according to the present invention can be prepared by proteolytic hydrolysis of the antibody or by expression in E. coli or mammalian cells (e.g. Chinese hamster ovary cell culture or other protein expression systems) of DNA encoding the fragment. Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods. For example, antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted F(ab′)2. This fragment can be further cleaved using a thiol reducing agent, and optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages, to produce 3.5S Fab′ monovalent fragments. Alternatively, an enzymatic cleavage using pepsin produces two monovalent Fab′ fragments and an Fc fragment directly. These methods are described, for example, by Goldenberg, U.S. Pat. Nos. 4,036,945 and 4,331,647, and references contained therein, which patents are hereby incorporated by reference in their entirety. See also Porter, R. R. [Biochem. J. 73: 119-126 (1959)]. Other methods of cleaving antibodies, such as separation of heavy chains to form monovalent light-heavy chain fragments, further cleavage of fragments, or other enzymatic, chemical, or genetic techniques may also be used, so long as the fragments bind to the antigen that is recognized by the intact antibody.
- Fv fragments comprise an association of VH and VL chains. This association may be noncovalent, as described in Inbar et al. [Proc. Nat'l Acad. Sci. USA 69:2659-62 (19720]. Alternatively, the variable chains can be linked by an intermolecular disulfide bond or cross-linked by chemicals such as glutaraldehyde. Preferably, the Fv fragments comprise VH and VL chains connected by a peptide linker. These single-chain antigen binding proteins (sFv) are prepared by constructing a structural gene comprising DNA sequences encoding the VH and VL domains connected by an oligonucleotide. The structural gene is inserted into an expression vector, which is subsequently introduced into a host cell such as E. coli. The recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging the two V domains. Methods for producing sFvs are described, for example, by [Whitlow and Filpula, Methods 2: 97-105 (1991); Bird et al., Science 242:423-426 (1988); Pack et al., Bio/Technology 11:1271-77 (1993); and U.S. Pat. No. 4,946,778, which is hereby incorporated by reference in its entirety.
- Another form of an antibody fragment is a peptide coding for a single complementarity-determining region (CDR). CDR peptides (“minimal recognition units”) can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody-producing cells. See, for example, Larrick and Fry [Methods, 2: 106-10 (1991)]. According to some embodiments of the present invention, the CDRs can be implemented in any form of an antibody such as by the use of recombinant DNA technology.
- Humanized forms of non-human (e.g., murine) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab′, F(ab′).sub.2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues form a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)].
- Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as import residues, which are typically taken from an import variable domain. Humanization can be essentially performed following the method of Winter and co-workers [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such humanized antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.
- Human antibodies can also be produced using various techniques known in the art, including phage display libraries [Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)]. The techniques of Cole et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985) and Boerner et al., J. Immunol., 147(1):86-95 (1991)1. Similarly, human antibodies can be made by introduction of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks et al., Bio/Technology 10: 779-783 (1992); Lonberg et al., Nature 368: 856-859 (1994); Morrison, Nature 368 812-13 (1994); Fishwild et al., Nature Biotechnology 14, 845-51 (1996); Neuberger, Nature Biotechnology 14: 826 (1996); and Lonberg and Huszar, Intern. Rev. Immunol. 13, 65-93 (1995).
- According to some embodiments of the invention, the antibody is attached to a cytotoxic moiety.
- According to some embodiments of the invention, the antibody is attached to an identifiable moiety.
- The identifiable moiety can be a member of a binding pair, which is identifiable via its interaction with an additional member of the binding pair and a label which is directly visualized. In one example, the member of the binding pair is an antigen which is identified by a corresponding labeled antibody. In one example, the label is a fluorescent protein or an enzyme producing a colorimetric reaction.
- The following Table 1 provides examples of sequences of identifiable moieties.
-
TABLE 1 Amino Acid Nucleic Acid sequence sequence (Genebank (Genebank Identifiable Moiety Accession No.) Accession No.) Green Fluorescent protein AAL33912 AF435427 Alkaline phosphatase AAK73766 AY042185 Peroxidase NP_568674 NM_124071 Histidine tag AAK09208 AF329457 Myc tag AF329457 AF329457 Biotin lygase tag NP_561589 NC_003366 orange fluorescent protein AAL33917 AF435432 Beta galactosidase NM_125776 NM_125776 Fluorescein isothiocyanate AAF22695 AF098239 Streptavidin S11540 S11540 - The cytotoxic or therapeutic moiety can be, for example, a cytotoxic moiety, a toxic moiety, a cytokine moiety, a bi-specific antibody moiety, a cytotoxin, a chemokine, a chemotherapy, a pro-apoptotic, interferon, a radioactive moiety, or combinations thereof, examples of which are provided infra.
- The following Table 2 provides examples of sequences of therapeutic moieties.
-
TABLE 2 Amino acid Nucleic acid sequence sequence (GenBank (GenBank Therapeutic moiety Accession No.) Accession No.) Pseudomonas exotoxin ABU63124 EU090068 Diphtheria toxin AAV70486 AY820132.1 interleukin 2CAA00227 A02159 CD3 P07766 X03884 CD16 NP_000560.5 NM_000569.6 interleukin 4NP_000580.1 NM_000589.2 HLA-A2 P01892 K02883 interleukin 10 P22301 M57627 Ricin toxin EEF27734 EQ975183 - It will be appreciated that such fusions can be effected using chemical conjugation or by recombinant DNA technology.
- The antibody of the present invention can decrease the inhibitory CEACAM1 homophilic (or homotypic) or heterotypic interactions to thereby augment the activity of lymphocytes. CEACAM1 homophilic interactions occur through the N-domain. Several amino acids are crucial for this interaction, including R43, Q44, D64 and R82. The interaction causes phosphorylation of a cytoplasmic tyrosine residue that recruits SHP-1 phosphatase. This initiates an inhibitory cascade within the lymphocytes, which targets proximal mediators, such as ZAP70.
- Thus, the antibody of the present invention can be used to block CEACAM1 on either or both immune effector cells (CEACAM1 expressing lymphocytes e.g., tumor infiltrating cells, T cells or NK cells) and target cells (e.g., CEACAM1 expressing pathological cells such as cancer cells). Examples of cancer cells which are candidates for this therapy include, but are not limited to, melanoma, lung, thyroid, breast, colon, prostate, hepatic, bladder, renal, cervical, pancreatic, leukemia, lymphoma, myeloid, ovarian, uterus, sarcoma, biliary, or endometrial cells.
- The present invention also contemplates isolated antibodies or antibody fragments that compete for binding to CEACAM1 with the antibodies produced by the above-described hybridoma cell. Those antibodies may be humanized, xenogeneic, or chimeric antibodies (as described in detail above) being suitable for e.g. therapeutic applications. An antibody fragment of the antibody can be, for example, a single chain Fv fragment, an F(ab′) fragment, an F(ab) fragment, and an F(ab′)2 fragment.
- Thus, according to a further aspect of the invention there is provided a method of rendering a CEACAM1 expressing tumor cell susceptible to immunomodulation. The method comprising contacting the CEACAM1 expressing tumor cell (e.g., melanoma, lung, thyroid, breast, colon, prostate, hepatic, bladder, renal, cervical, pancreatic, leukemia, lymphoma, myeloid, ovarian, uterus, sarcoma, biliary or endometrial cell) with the antibody or antibody fragment described above, thereby rendering the CEACAM1 expressing tumor cell susceptible to immunomodulation.
- As used herein “immunomodulation” refers to lymphocyte dependent immunomodulation (e.g., by NK cells or tumor infiltrating lymphocytes).
- Additionally or alternatively, the present invention also envisages a method of immunomodulation (e.g., inhibiting CEACAM1 homotypic or heterotypic protein-protein interaction), by contacting a CEACAM1-expressing lymphocyte with the antibody or antibody fragment described herein.
- The methods of the present teachings can be effected in-vitro, ex-vivo (e.g., used in T cell based adoptive immunotherapy) or in-vivo.
- As mentioned, antibodies of some embodiments of the invention can have anti cancer activity which is independent from its immunomodulatory activity described above.
- Thus, the present teachings further provide for a method of inhibiting migration or proliferation of a CEACAM1 expressing tumor cell, the method comprising contacting the CEACAM1 expressing tumor cell with the antibody or antibody fragment described herein, thereby inhibiting migration or proliferation of a CEACAM1 expressing tumor cell.
- As used herein “inhibiting” refers to at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% 100% inhibition in proliferation or migration which can be assayed using methods which are well known in the art (see examples section below).
- Antibodies of the present invention can be effectively used for the treatment of cancer.
- Thus according to a further aspect there is provided a method of treating cancer, the method comprising administering to a subject in need thereof a therapeutically effective amount of the antibody or antibody fragment described herein, thereby treating the cancer in the subject. Examples of cancer which can be diagnosed or treated according to the present teachings include, but are not limited to, melanoma, sarcoma, lung cancer, cancer of the thyroid, breast cancer, colon cancer, prostate cancer, hepatic cancer, bladder cancer, renal cancer, cervical cancer, pancreatic cancer, leukemia, lymphoma, myeloid cell related cancer, ovarian cancer, uterus cancer, biliary cancer or endometrial cancer.
- According to a specific embodiment of the present invention, the cancer is melanoma.
- The term “treating” refers to inhibiting, preventing or arresting the development of a pathology (disease, disorder or condition) and/or causing the reduction, remission, or regression of a pathology. Those of skill in the art will understand that various methodologies and assays can be used to assess the development of a pathology, and similarly, various methodologies and assays may be used to assess the reduction, remission or regression of a pathology.
- As used herein, the term “preventing” refers to keeping a disease, disorder or condition from occurring in a subject who may be at risk for the disease, but has not yet been diagnosed as having the disease.
- As used herein, the term “subject” includes mammals, preferably human beings at any age which suffer from the pathology. Preferably, this term encompasses individuals who are at risk to develop the pathology.
- In order to enhance treatment (e.g. cancer treatment), lymphocytes such as T cells (e.g. Tumor Infiltrating Lymphocytes) or NK cells may be administered to the subject prior to, concomitantly with or following administration of the antibody or antibody fragment of the present invention. Accordingly, lymphocytes may be obtained from the subject (e.g. from the peripheral blood or from the tumor of same) or from a donor (an allogeneic or a syngeneic lymphocyte donor), treated by ex-vivo expansion methods as to obtained viable lymphocytes [e.g. by growth on irradiated feeder layer supplemented with IL-2, as previously described in Besser M J et al., Clin Cancer Res (Epub ahead of print) 2010 May 1 and in Besser M J et al., Journal of Immunotherapy (Epub ahead of print) 2009 Apr. 1, fully incorporated herein by reference] and administered to the subject.
- It will be appreciated that the subject may be treated by any other anti-cancer treatment (e.g. chemotherapy, radiation therapy, etc.) prior to administration of the antibody or antibody fragment or prior to administration of the lymphocytes.
- The antibody of the present invention can be administered to an organism per se, or in a pharmaceutical composition where it is mixed with suitable carriers or excipients.
- As used herein a “pharmaceutical composition” refers to a preparation of one or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.
- Herein the term “active ingredient” refers to the antibody accountable for the biological effect.
- Hereinafter, the phrases “physiologically acceptable carrier” and “pharmaceutically acceptable carrier” which may be interchangeably used refer to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound. An adjuvant is included under these phrases.
- Herein the term “excipient” refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient. Examples, without limitation, of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.
- Techniques for formulation and administration of drugs may be found in “Remington's Pharmaceutical Sciences,” Mack Publishing Co., Easton, Pa., latest edition, which is incorporated herein by reference.
- Suitable routes of administration may, for example, include oral, rectal, transmucosal, especially transnasal, intestinal or parenteral delivery, including intramuscular, subcutaneous and intramedullary injections as well as intrathecal, direct intraventricular, intracardiac, e.g., into the right or left ventricular cavity, into the common coronary artery, intravenous, inrtaperitoneal, intranasal, or intraocular injections.
- Conventional approaches for drug delivery to the central nervous system (CNS) include: neurosurgical strategies (e.g., intracerebral injection or intracerebroventricular infusion); molecular manipulation of the agent (e.g., production of a chimeric fusion protein that comprises a transport peptide that has an affinity for an endothelial cell surface molecule in combination with an agent that is itself incapable of crossing the BBB) in an attempt to exploit one of the endogenous transport pathways of the BBB; pharmacological strategies designed to increase the lipid solubility of an agent (e.g., conjugation of water-soluble agents to lipid or cholesterol carriers); and the transitory disruption of the integrity of the BBB by hyperosmotic disruption (resulting from the infusion of a mannitol solution into the carotid artery or the use of a biologically active agent such as an angiotensin peptide). However, each of these strategies has limitations, such as the inherent risks associated with an invasive surgical procedure, a size limitation imposed by a limitation inherent in the endogenous transport systems, potentially undesirable biological side effects associated with the systemic administration of a chimeric molecule comprised of a carrier motif that could be active outside of the CNS, and the possible risk of brain damage within regions of the brain where the BBB is disrupted, which renders it a suboptimal delivery method.
- Alternately, one may administer the pharmaceutical composition in a local rather than systemic manner, for example, via injection of the pharmaceutical composition directly into a tissue region of a patient.
- The term “tissue” refers to part of an organism consisting of an aggregate of cells having a similar structure and/or a common function. Examples include, but are not limited to, brain tissue, retina, skin tissue, hepatic tissue, pancreatic tissue, bone, cartilage, connective tissue, blood tissue, muscle tissue, cardiac tissue brain tissue, vascular tissue, renal tissue, pulmonary tissue, gonadal tissue, hematopoietic tissue.
- Pharmaceutical compositions of the present invention may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
- Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active ingredients into preparations which, can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
- For injection, the active ingredients of the pharmaceutical composition may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological salt buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
- For oral administration, the pharmaceutical composition can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the pharmaceutical composition to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for oral ingestion by a patient. Pharmacological preparations for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carbomethylcellulose; and/or physiologically acceptable polymers such as polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
- Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
- Pharmaceutical compositions which can be used orally, include push-fit capsules made of gelatin as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules may contain the active ingredients in admixture with filler such as lactose, binders such as starches, lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active ingredients may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for the chosen route of administration.
- For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.
- For administration by nasal inhalation, the active ingredients for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from a pressurized pack or a nebulizer with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane or carbon dioxide. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in a dispenser may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
- The pharmaceutical composition described herein may be formulated for parenteral administration, e.g., by bolus injection or continuos infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multidose containers with optionally, an added preservative. The compositions may be suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- Pharmaceutical compositions for parenteral administration include aqueous solutions of the active preparation in water-soluble form. Additionally, suspensions of the active ingredients may be prepared as appropriate oily or water based injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acids esters such as ethyl oleate, triglycerides or liposomes. Aqueous injection suspensions may contain substances, which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the active ingredients to allow for the preparation of highly concentrated solutions.
- Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water based solution, before use.
- The pharmaceutical composition of the present invention may also be formulated in rectal compositions such as suppositories or retention enemas, using, e.g., conventional suppository bases such as cocoa butter or other glycerides.
- Pharmaceutical compositions suitable for use in context of the present invention include compositions wherein the active ingredients are contained in an amount effective to achieve the intended purpose. More specifically, a therapeutically effective amount means an amount of active ingredients effective to prevent, alleviate or ameliorate symptoms of a disorder (e.g., cancer) or prolong the survival of the subject being treated.
- Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
- For any preparation used in the methods of the invention, the therapeutically effective amount or dose can be estimated initially from in vitro and cell culture assays. For example, a dose can be formulated in animal models to achieve a desired concentration or titer. Such information can be used to more accurately determine useful doses in humans.
- Toxicity and therapeutic efficacy of the active ingredients described herein can be determined by standard pharmaceutical procedures in vitro, in cell cultures or experimental animals. The data obtained from these in vitro and cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage may vary depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g., Fingl, et al., 1975, in “The Pharmacological Basis of Therapeutics”, Ch. 1 p.1).
- Dosage amount and interval may be adjusted individually to provide antibody levels of the active ingredient are sufficient to induce or suppress the biological effect (minimal effective concentration, MEC). The MEC will vary for each preparation, but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. Detection assays can be used to determine plasma concentrations.
- Therapeutic efficacy can be further validated in correlative animal models which are well known in the art. Human xenografts in immunodeficient mice. Depending on the severity and responsiveness of the condition to be treated, dosing can be of a single or a plurality of administrations, with course of treatment lasting from several days to several weeks or until cure is effected or diminution of the disease state is achieved.
- The amount of a composition to be administered will, of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, etc.
- Compositions of the present invention may, if desired, be presented in a pack or dispenser device, such as an FDA approved kit, which may contain one or more unit dosage forms containing the active ingredient. The pack may, for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accommodated by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or human or veterinary administration. Such notice, for example, may be of labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert. Compositions comprising a preparation of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition, as is further detailed above.
- Aside from therapeutic applications, antibodies of the present invention can also be used in diagnostic applications.
- Thus, according to a further aspect there is provided a method for diagnosing a cancer in a subject in need thereof, the method comprising contacting a biological sample derived from the subject (in-vivo or ex-vivo) with the antibody or antibody fragment described herein, wherein a complex formation beyond a predetermined threshold is indicative of the cancer in the subject. According to some embodiments, cells of the cancer are characterized by over expression of CEACAM1 as compared to unaffected cells.
- As mentioned, the method of the invention is effected under conditions sufficient to form an immunocomplex; such conditions (e.g., appropriate concentrations, buffers, temperatures, reaction times) as well as methods to optimize such conditions are known to those skilled in the art, and examples are disclosed herein. As used herein the phrase “immunocomplex” refers to a complex which comprises the antibody of the invention and the CEACAM1.
- Determining a presence or level of the immunocomplex of the invention may be direct or by detecting an identifiable (detectable) moiety which may be attached to the antibody.
- The level of the immunocomplex in the tested cell (e.g., a cell of a subject in need thereof) is compared to a predetermined threshold. It will be appreciated that the antibody of the present invention can also be used to measure the amount of serum soluble CEACAM1. Regardless, the threshold may be determined based on a known reference level and/or a level in a control cell or serum. The control cell can be obtained from a control, healthy subject (e.g., a subject not suffering from the cancer) or from the same subject prior to disease initiation or following treatment. According to some embodiments of the invention, the control subject is of the same species e.g. human, preferably matched with the same age, weight, sex etc. as the subject in need thereof.
- As used herein the term “diagnosing” refers to determining presence or absence of a pathology, classifying a pathology or a symptom, determining a severity of the pathology, monitoring pathology progression, forecasting an outcome of a pathology and/or prospects of recovery.
- To facilitate diagnosis, the above teachings can be combined with other methods of diagnosing cancer which are well known in the art include but are not limited to imaging, molecular tests and surgical biopsies.
- Once the diagnosis is established the subject is informed of the diagnosis and suitable treatments may be initiated.
- The terms “comprises”, “comprising”, “includes”, “including”, “having” and their conjugates mean “including but not limited to”. This term encompasses the terms “consisting of” and “consisting essentially of”.
- The phrase “consisting essentially of” means that the composition or method may include additional ingredients and/or steps, but only if the additional ingredients and/or steps do not materially alter the basic and novel characteristics of the claimed composition or method.
- As used herein, the singular form “a”, “an” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a compound” or “at least one compound” may include a plurality of compounds, including mixtures thereof.
- Throughout this application, various embodiments of this invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
- Whenever a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range. The phrases “ranging/ranges between” a first indicate number and a second indicate number and “ranging/ranges from” a first indicate number “to” a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.
- As used herein the term “method” refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.
- The word “exemplary” is used herein to mean “serving as an example, instance or illustration”. Any embodiment described as “exemplary” is not necessarily to be construed as preferred or advantageous over other embodiments and/or to exclude the incorporation of features from other embodiments.
- The word “optionally” is used herein to mean “is provided in some embodiments and not provided in other embodiments”. Any particular embodiment of the invention may include a plurality of “optional” features unless such features conflict.
- It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.
- Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find experimental support in the following examples.
- Reference is now made to the following examples, which together with the above descriptions, illustrate some embodiments of the invention in a non limiting fashion.
- Generally, the nomenclature used herein and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques. Such techniques are thoroughly explained in the literature. See, for example, “Molecular Cloning: A laboratory Manual” Sambrook et al., (1989); “Current Protocols in Molecular Biology” Volumes I-III Ausubel, R. M., ed. (1994); Ausubel et al., “Current Protocols in Molecular Biology”, John Wiley and Sons, Baltimore, Md. (1989); Perbal, “A Practical Guide to Molecular Cloning”, John Wiley & Sons, New York (1988); Watson et al., “Recombinant DNA”, Scientific American Books, New York; Birren et al. (eds) “Genome Analysis: A Laboratory Manual Series”, Vols. 1-4, Cold Spring Harbor Laboratory Press, New York (1998); methodologies as set forth in U.S. Pat. Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057; “Cell Biology: A Laboratory Handbook”, Volumes I-III Cellis, J. E., ed. (1994); “Current Protocols in Immunology” Volumes I-III Coligan J. E., ed. (1994); Stites et al. (eds), “Basic and Clinical Immunology” (8th Edition), Appleton & Lange, Norwalk, Conn. (1994); Mishell and Shiigi (eds), “Selected Methods in Cellular Immunology”, W. H. Freeman and Co., New York (1980); available immunoassays are extensively described in the patent and scientific literature, see, for example, U.S. Pat. Nos. 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,879,219; 5,011,771 and 5,281,521; “Oligonucleotide Synthesis” Gait, M. J., ed. (1984); “Nucleic Acid Hybridization” Hames, B. D., and Higgins S. J., eds. (1985); “Transcription and Translation” Hames, B. D., and Higgins S. J., Eds. (1984); “Animal Cell Culture” Freshney, R. I., ed. (1986); “Immobilized Cells and Enzymes” IRL Press, (1986); “A Practical Guide to Molecular Cloning” Perbal, B., (1984) and “Methods in Enzymology” Vol. 1-317, Academic Press; “PCR Protocols: A Guide To Methods And Applications”, Academic Press, San Diego, Calif. (1990); Marshak et al., “Strategies for Protein Purification and Characterization—A Laboratory Course Manual” CSHL Press (1996); all of which are incorporated by reference as if fully set forth herein. Other general references are provided throughout this document. The procedures therein are believed to be well known in the art and are provided for the convenience of the reader. All the information contained therein is incorporated herein by reference.
- Generation of MRG1 Monoclonal Antibodies
- A monoclonal antibody that effectively blocks the CEACAM1 homophilic interactions in vitro at nanomolar concentrations was generated. Briefly, mice were immunized 3 times, at 2 week intervals, with 5 micrograms of recombinant human CEACAM1 (entire protein, commercially available from R&D Systems). Splenocytes were harvested and fused with SP2/0 cells, to generate a hybridoma library.
- The hybridoma producing the CEACAM1-blocking antibody (MRG1 mAb) was re-cloned several times to yield a stable clone.
- Other Monoclonal Antibodies
- Kat4c mAb and rabbit polyclonal anti-CEACAM were purchased from DAKO (Glostrup, Denmark).
- Materials and Experimental Procedures
- Generation of CEACAM Expressing Cells
- CEACAM-negative 721.221 human cells (parental B cells) were stably transfected with CEACAM1, CEACAM5, CEACAM6 or CEACAM8 by electroporation and selection with G418.
- The murine thymoma BW parental cells (cells that lack TCR alpha and beta chains, yet retain full secretion machinery of IL-2) were transfected with a chimeric molecule comprising the extracellular portion of human CEACAM1 fused to the transmembrane and cytosolic tail of murine zeta chain. Transfection was performed by electroporation and selection with G418.
- Antibody Screening by FACS
- Hybridomas were screened for CEACAM1 binding activity by flow cytometry as follows:
- (a) 50,000 transfected CEACAM cells were placed in 96-U shaped wells.
- (b) The cells were washed with cold FACS buffer (PBS, BSA 0.5%, Azide 0.05%).
- (c) The cells were incubated with the staining mAb (MRG1 or Kat4c): 0.1 micrograms of mAb per 100 microliters, for 30 minutes, on ice.
- (d) The cells were centrifuged, supernatants were removed and the cells were resuspended in 100 microliter FITC-conjugated goat anti mouse antibodies (Jackson Immunoresearch) at a dilution of 1:200.
- (e) After 30 minute incubation (on ice in dark conditions), the cells were centrifuged, washed and re-suspended in FACS buffer.
- (f) Cells were analyzed using a FACScalibur and CellQuest software.
- Results
- As 721.221 parental cells do not express any of the CEACAM proteins, these cells were stably transfected with CEACAM1, CEACAM5, CEACAM6 or CEACAM8 in order to test the specificity of the CEACAM1 monoclonal antibodies (mAbs). The hybridomas were then screened for CEACAM1 binding activity by flow cytometry. As shown in
FIG. 1A , the MRG1 mAb generated according to the present teachings is specific to human CEACAM1. It has an insignificant cross-reactivity to CEACAM5 and no binding to CEACAM6 or CEACAM8.FIG. 1B shows that all transfectants expressed CEACAM molecules, with CEACAM1 being the lowest, which emphasizes the specificity pattern of MRG1. - Materials and Experimental Procedures
- Antibody Screening by ELISA
- CEACAM1 blocking activity was tested using a BW functional system. The BW functional system comprises a mouse cell line (BW) stably transfected with a chimeric molecule comprising the extracellular domain of human CEACAM1 fused to mouse zeta chain (BW/CEACAM1-zeta, see Example 2, above). Co-incubation of the BW/CEACAM1-zeta cells with other CEACAM1-positive cells resulted in the secretion of measurable concentrations of mouse IL-2.
- Thus, BW/CEACAM1-zeta (effector cells) or 221/CEACAM1 (target cells) were each pre-incubated separately with 10-40 ng/ml MRG1 mAb. Following one hour incubation on ice, the reciprocal cells (221/CEACAM1 or BW/CEACAM1) were added and the secretion of mouse IL-2 was measured by sandwich ELISA (R&D systems).
- Cytotoxicity Assay
- Cytotoxicity assays testing the killing of various melanoma lines by tumor infiltrating lymphocytes was performed in the presence or absence of 1 μg/ml MRG1 mAb. CEACAM1High 526 mel, 624mel and CEACAM1dim 09 mel melanoma cells were used as target cells. TIL014 cells were used as effector cells at an E:T ratio of 10:1. Following one hour incubation with the MRG1 mAb on ice, the reciprocal cells were added and co-incubated for 5 hours at 37° C. Target cells were pre-labeled with a green fluorescent dye (CFSE) and specific lysis was determined by Propidium Iodide (PI) co-staining in flow cytometry. Spontaneous death was subtracted.
- Results
- The capability of the purified MRG1 mAb to inhibit CEACAM1 homophilic binding was verified. As shown in
FIG. 2 , the purified mAb MRG1 showed a dose-dependant inhibition of CEACAM1 homophilic binding. At a concentration of 10 ng/ml, the mAb efficiently reduced CEACAM1 interactions, effectively reaching a plateau at a concentration of 20 ng/ml. Importantly, the two experimental settings i.e. the addition of MRG1 mAb to the effector cells, BW/CEACAM1-zeta, or to the target cells, 221/CEACAM1, showed similar results (secretion of the mouse IL-2 was effectively blocked). - The blocking effect of MRG1 mAb was further demonstrated in cytotoxicity assays. As shown if
FIG. 3 , killing of the CEACAM1high 526 mel and 624mel cells was enhanced by incubation of the antibody with effector cells (but not on target cells). The killing of the CEACAM1thm 09 mel cells was unaffected by the presence of MRG1 mAb (FIG. 3 ). - Materials and Experimental Procedures
- Invasion Assay
- The blocking effect of the antibodies was tested in an invasion assay. Briefly, melanoma cells (08mel or 09mel) were pre-incubated in the presence or absence of 1 μg/ml MRG1 mAb and then tested by Matrigel invasion assays. Invasion was allowed for 24 hours and the amount of invading cells was quantified with standardized XTT.
- Net Proliferation Assay
- CEACAM1High 526 mel cells were seeded on
day 0 in 48-well plates (2,500 cells per well). On seeding, MRG1 was added in 3 different concentrations (0.5, 1, or 3 μg/ml), or not added at all. Total viable cells were counted 2 days or 5 days after seeding. Proliferation was determined with standardized XTT and by direct cell counting. - Results
- As shown in
FIG. 4 , MRG1 blocked the invasion of CEACAM1-positive 08mel cells (CEACAM1 expression level was medium, i.e. median fluorescence intensity of CEACAM1 expression was 50) and had little or no effect on CEACAM1dim 09mel cells (CEACAM1 expression level was low, i.e. median fluorescence intensity of CEACAM1 expression was 15). - MRG1 was also tested in net proliferation assays. A dose-dependent inhibition in net proliferation of 526mel cells was observed (
FIG. 5 ). Following 5 days of treatment, proliferation was reduced by more than 60% (with 3 μg MRG1 mAb). - Materials and Experimental Procedures
- Melanoma Xenograft Models
- 5×106 CEACAM1+ human melanoma cells were injected subcutaneously to the flank of 7 week old SCID-NOD mice. Tumor masses formed in 100% of the mice within 14-17 days and continued to grow. Tumor dimensions were monitored non-invasively with a caliper 3 times a week and volume approximation was calculated as (d1×d2×d3/2).
- Administration of MRG1 was performed by injection of 0.5 mg antibody diluted in 0.5 ml sterile PBS intraperitoneally. Injection of PBS served as control.
- Administration of reactive human anti-melanoma lymphocytes was performed by intravenous injection into the tail vein of 20×106 cells diluted in 200 μl of sterile PBS.
- Results
- In line with the blocking functions demonstrated above, administration of MRG1 antibody inhibited tumor growth. This effect was evident when the antibody was administered at the time of tumor cell inoculation (
FIG. 6A , “Prevention setup”) or after a measurable tumor mass was already formed (FIG. 6B , “Treatment setup”). These effects were evident after 4 injections within 8 days, followed by non-invasive monitoring (see arrows inFIG. 6 ). It should be noted that this effect was independent of any immunomodulating effect, as SCID-NOD mice are immunodeficient. - Simulation of anti-melanoma immune response was performed by a single intravenous injection of reactive human anti-melanoma lymphocytes, which inhibited tumor growth (
FIG. 7 ). This effect was significantly enhanced by intraperitoneal MRG1 injections once a week. - Materials and Experimental Procedures
- Antibody Screening by ELISA
- CEACAM1 blocking activity was tested using a BW functional system as described in detail in Example 3, hereinabove.
- 100,000 BW/CEACAM1-zeta cells were pre-incubated with 15 ng/ml MRG1 mAb, 2600 ng/ml Kat4c mAb or 600 ng/ml rabbit polyclonal anti-CEACAM antibody. Following one hour incubation on ice, 50,000 721.221/CEACAM1 cells were added and the secretion of mouse IL-2 was measured by sandwich ELISA (R&D Systems).
- Results
- As depicted in Example 3, hereinabove, the inventors demonstrated a nearly complete blocking of CEACAM1 activity using 15 ng/ml MRG1 mAb. In contrast, the anti-CEACAM1 monoclonal antibody Kat4c was able to yield a minor blocking effect only when 200-fold higher concentrations were tested and the polyclonal rabbit anti-CEACAM antibody yielded a similar inhibitory effect with 40-fold higher concentration (2600 ng/ml and 600 ng/ml, respectively,
FIG. 8 ). - Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.
- All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. To the extent that section headings are used, they should not be construed as necessarily limiting.
Claims (29)
1. A hybridoma cell which has been deposited under ATCC Accession Number PTA-9974.
2. An isolated antibody or antibody fragment comprising an antigen recognition domain having the CDR sequences and orientation of the antibody produced from the hybridoma cell of claim 1 .
3. A method of immunomodulation, the method comprising contacting a CEACAM1-expressing lymphocyte with the antibody or antibody fragment of claim 2 .
4. A method of inhibiting migration or proliferation of a CEACAM1 expressing tumor cell, the method comprising contacting the CEACAM1 expressing tumor cell with the antibody or antibody fragment of claim 2 , thereby inhibiting migration or proliferation of a CEACAM1 expressing tumor cell.
5. A method of inhibiting CEACAM1 homotypic or heterotypic protein-protein interaction, the method comprising contacting a CEACAM1-expressing lymphocyte with the antibody or antibody fragment of claim 2 , thereby inhibiting CEACAM1 homotypic or heterotypic protein-protein interaction.
6. A pharmaceutical composition comprising as an active ingredient the antibody or antibody fragment of claim 2 .
7. A method for diagnosing a cancer characterized by over expression of CEACAM1 in a subject in need thereof, the method comprising: (i) contacting a control biological sample with an anti-CEACAM1 antibody or antibody fragment that recognizes CEACAM1 and comprises the same CDR sequences in the same orientation as the CDRs of the antibody produced from a hybridoma cell which has been deposited under ATCC Accession Number PTA-9974; (ii) contacting a biological sample suspected of having cancerous cells derived from the subject with the anti-CEACAM1 antibody or antibody fragment that recognizes CEACAM1; (iii) determining the levels of the immune-complexes formed in (i) and (ii); and (iv) comparing these levels; wherein a significantly higher level of immune-complex formation in the biological sample from the subject compared to the control biological sample is indicative of cancer in said subject.
8. The method of claim 7 , wherein said level of said immune-complex is determined by detecting a detectable moiety attached to said antibody or antibody fragment.
9. The method of claim 7 , wherein the control biological sample is: (i) a control cell; or (ii) a control serum.
10. The method of claim 7 , wherein the control biological sample is obtained from said subject: (i) prior to disease initiation; or (ii) following at least one previous treatment.
11. The method of claim 7 , combined with an additional method of diagnosing cancer selected from the group consisting of an imaging step of said subject, a molecular test, a surgical biopsy step, and a combination thereof.
12. The method of claim 11 , wherein the imaging step is performed to assist biopsy acquisition from said subject.
13. The method of claim 11 , wherein the molecular test is for detection of an additional cancer-related marker in said biological sample.
14. The method of claim 11 , wherein the surgical biopsy is for obtaining a biological sample from said subject.
15. A method for diagnosing the severity of a cancer characterized by over expression of CEACAM1 in a subject in need thereof, the method comprising: (i) contacting a control biological sample with an anti-CEACAM1 antibody or antibody fragment that recognizes CEACAM1 that comprises the same CDR sequences in the same orientation as the CDRs of the antibody produced from a hybridoma cell which has been deposited under ATCC Accession Number PTA-9974; (ii) contacting a biological sample suspected of having cancerous cells derived from the subject with the anti-CEACAM1 antibody or antibody fragment that recognizes CEACAM1; (iii) determining the levels of the immune-complexes formed in (i) and (ii); and (iv) comparing these levels; wherein a significantly higher level of immune-complex formation in the biological sample from the subject compared to the control biological sample is indicative of the severity of the cancer in said subject.
16. A method of treating cancer, the method comprising administering to a subject in need thereof a therapeutically effective amount of the antibody or antibody fragment that recognizes CEACAM1 and comprises the same CDR sequences in the same orientation as the CDRs of the antibody produced from a hybridoma cell which has been deposited under ATCC Accession Number PTA-9974; and further administering to the subject lymphocytes.
17. The method of claim 16 wherein the antibody or antibody fragment is attached to a cytotoxic moiety.
18. The method of claim 17 wherein said cytotoxic moiety comprises a cytotoxin, a chemokine, a chemotherapy, a pro-apoptotic, an interferon, a radioactive moiety, or combinations thereof.
19. The method of claim 16 wherein the lymphocytes are CEACAM1-expressing lymphocytes.
20. The method of claim 19 wherein the CEACAM1-expressing lymphocytes are Tumor Infiltrating Lymphocyte or NK cells.
21. The method of claim 19 wherein the CEACAM1-expressing lymphocytes are cytotoxic T cells.
22. The method of claim 19 wherein the lymphocytes are administered to the subject prior to administration of the antibody or antibody fragment.
23. The method of claim 19 wherein the lymphocytes are administered to the subject concomitantly administration of the antibody or antibody fragment.
24. The method of claim 19 wherein the lymphocytes are administered to the subject following administration of the antibody or antibody fragment.
25. The method of claim 19 wherein the lymphocytes are obtained from the subject and treated by ex-vivo expansion methods.
26. The method of claim 19 wherein the subject is treated by other anti-cancer treatment prior to administration of the antibody or antibody fragment or prior to administration of the lymphocytes.
27. The method of claim 32 wherein the other anti-cancer treatment is chemotherapy or radiation therapy.
28. The method of claim 16 wherein the cancer is selected from the group consisting of: melanoma, sarcoma, lung cancer, cancer of the thyroid, breast cancer, colon cancer, prostate cancer, hepatic cancer, bladder cancer, renal cancer, cervical cancer, pancreatic cancer, leukemia, lymphoma, myeloid cell related cancer, ovarian cancer, uterus cancer, biliary cancer or endometrial cancer.
29. The method of claim 16 wherein the cancer is melanoma.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/715,386 US20180016338A1 (en) | 2009-04-30 | 2017-09-26 | Anti ceacam1 antibodies and methods of using same |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21304009P | 2009-04-30 | 2009-04-30 | |
PCT/IL2010/000348 WO2010125571A1 (en) | 2009-04-30 | 2010-04-29 | Anti ceacam1 antibodies and methods of using same |
US201113318266A | 2011-12-21 | 2011-12-21 | |
US14/061,277 US9261507B2 (en) | 2009-04-30 | 2013-10-23 | Anti CEACAM1 antibodies and methods of using same |
US14/990,959 US20160176966A1 (en) | 2009-04-30 | 2016-01-08 | Anti ceacam1 antibodies and methods of using same |
US15/715,386 US20180016338A1 (en) | 2009-04-30 | 2017-09-26 | Anti ceacam1 antibodies and methods of using same |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/990,959 Continuation US20160176966A1 (en) | 2009-04-30 | 2016-01-08 | Anti ceacam1 antibodies and methods of using same |
Publications (1)
Publication Number | Publication Date |
---|---|
US20180016338A1 true US20180016338A1 (en) | 2018-01-18 |
Family
ID=42313044
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/318,266 Active US8598322B2 (en) | 2009-04-30 | 2010-04-29 | Anti CEACAM1 antibodies and methods of using same |
US14/061,277 Active US9261507B2 (en) | 2009-04-30 | 2013-10-23 | Anti CEACAM1 antibodies and methods of using same |
US14/990,959 Abandoned US20160176966A1 (en) | 2009-04-30 | 2016-01-08 | Anti ceacam1 antibodies and methods of using same |
US15/715,386 Abandoned US20180016338A1 (en) | 2009-04-30 | 2017-09-26 | Anti ceacam1 antibodies and methods of using same |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/318,266 Active US8598322B2 (en) | 2009-04-30 | 2010-04-29 | Anti CEACAM1 antibodies and methods of using same |
US14/061,277 Active US9261507B2 (en) | 2009-04-30 | 2013-10-23 | Anti CEACAM1 antibodies and methods of using same |
US14/990,959 Abandoned US20160176966A1 (en) | 2009-04-30 | 2016-01-08 | Anti ceacam1 antibodies and methods of using same |
Country Status (19)
Country | Link |
---|---|
US (4) | US8598322B2 (en) |
EP (2) | EP2424896B1 (en) |
JP (1) | JP5726170B2 (en) |
KR (2) | KR101875227B1 (en) |
CN (1) | CN102482354B (en) |
AU (1) | AU2010243211B2 (en) |
BR (1) | BRPI1015350B1 (en) |
CA (1) | CA2760385C (en) |
DK (1) | DK2424896T3 (en) |
ES (2) | ES2563527T3 (en) |
HK (2) | HK1167264A1 (en) |
HR (1) | HRP20151099T8 (en) |
HU (1) | HUE028294T2 (en) |
LT (1) | LT2990421T (en) |
PL (2) | PL2424896T3 (en) |
PT (1) | PT2424896E (en) |
RU (2) | RU2016134843A (en) |
SI (1) | SI2424896T1 (en) |
WO (1) | WO2010125571A1 (en) |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8815248B2 (en) * | 2005-06-09 | 2014-08-26 | Gal Markel | Modulation of immunity and CEACAM1 activity |
RU2016134843A (en) * | 2009-04-30 | 2018-12-11 | Тел Хашомер Медикал Рисерч Инфрастракче Энд Сервисиз Лтд. | ANTIBODIES TO CEACAM1 AND WAYS OF THEIR USE |
WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
CA2892371C (en) * | 2011-12-01 | 2021-01-19 | The Brigham And Women's Hospital, Inc. | Anti-ceacam1 recombinant antibodies for cancer therapy |
US10513540B2 (en) | 2012-07-31 | 2019-12-24 | The Brigham And Women's Hospital, Inc. | Modulation of the immune response |
US10081679B2 (en) * | 2013-11-25 | 2018-09-25 | Ccam Biotherapeutics Ltd. | Compositions comprising anti-CEACAM1 and anti-PD antibodies for cancer therapy |
CA2931684C (en) | 2013-12-19 | 2024-02-20 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
JOP20200094A1 (en) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-1 and uses thereof |
JOP20200096A1 (en) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | Antibody molecules to tim-3 and uses thereof |
AU2015229103C9 (en) | 2014-03-14 | 2020-11-26 | Immutep S.A.S | Antibody molecules to LAG-3 and uses thereof |
WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
CA2940671A1 (en) | 2014-04-07 | 2015-10-15 | Novartis Ag | Treatment of cancer using anti-cd19 chimeric antigen receptor |
CR20160534A (en) * | 2014-04-27 | 2017-04-25 | Ccam Biotherapeutics Ltd | HUMANIZED ANTIBODIES AGAINST THE CELLULAR ADHESION MOLECULE RELATED TO CARCINOEMBRIONIC ANTIGEN 1 (CEACAM1) |
US11427647B2 (en) | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
EP3193915A1 (en) | 2014-07-21 | 2017-07-26 | Novartis AG | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
SG10201913765YA (en) | 2014-07-21 | 2020-03-30 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
EP4205749A1 (en) | 2014-07-31 | 2023-07-05 | Novartis AG | Subset-optimized chimeric antigen receptor-containing cells |
WO2016025880A1 (en) | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using gfr alpha-4 chimeric antigen receptor |
DK3183268T3 (en) | 2014-08-19 | 2020-05-11 | Univ Pennsylvania | CANCER TREATMENT USING A CD123 CHEMICAL ANTIGEN RECEPTOR |
EP3925622A1 (en) | 2014-09-13 | 2021-12-22 | Novartis AG | Combination therapies |
CN114621969A (en) | 2014-09-17 | 2022-06-14 | 诺华股份有限公司 | Targeted cytotoxic cells with chimeric receptors for adoptive immunotherapy |
US20170209574A1 (en) | 2014-10-03 | 2017-07-27 | Novartis Ag | Combination therapies |
SG11201702895SA (en) | 2014-10-08 | 2017-05-30 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
TWI716362B (en) | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | Antibody molecules to pd-l1 and uses thereof |
US20180334490A1 (en) | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
US20170340733A1 (en) | 2014-12-19 | 2017-11-30 | Novartis Ag | Combination therapies |
WO2016120331A1 (en) | 2015-01-28 | 2016-08-04 | Karl Sebastian Lang | Agonistic anti-cd66cd66 antibody for antiviral therapy |
US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
ES2876974T3 (en) | 2015-04-07 | 2021-11-15 | Novartis Ag | Combination therapy with chimeric antigen receptor and amino pyrimidine derivatives |
AU2016249005B2 (en) | 2015-04-17 | 2022-06-16 | Novartis Ag | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
EP3325504A1 (en) | 2015-07-21 | 2018-05-30 | Novartis AG | Methods for improving the efficacy and expansion of immune cells |
US20180222982A1 (en) | 2015-07-29 | 2018-08-09 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
EP3316902A1 (en) | 2015-07-29 | 2018-05-09 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
LT3317301T (en) | 2015-07-29 | 2021-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
CN108780084B (en) | 2015-09-03 | 2022-07-22 | 诺华股份有限公司 | Biomarkers predictive of cytokine release syndrome |
JP2019500893A (en) | 2015-11-03 | 2019-01-17 | ヤンセン バイオテツク,インコーポレーテツド | Antibodies that specifically bind to PD-1 and TIM-3 and uses thereof |
US20180371093A1 (en) | 2015-12-17 | 2018-12-27 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
EP3389720A1 (en) | 2015-12-18 | 2018-10-24 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
EP3389711A1 (en) | 2015-12-18 | 2018-10-24 | Novartis AG | Antibodies targeting cd32b and methods of use thereof |
EP3393504A1 (en) | 2015-12-22 | 2018-10-31 | Novartis AG | Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy |
AU2017225733A1 (en) | 2016-03-04 | 2018-09-27 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore |
CN109641947B (en) | 2016-07-20 | 2023-04-14 | 犹他大学研究基金会 | CD229CAR T cells and methods of use thereof |
CA3029926C (en) * | 2016-07-25 | 2023-01-03 | Shizuoka Prefecture | Diagnostic biomarker for extrahepatic bile duct cancer, intrahepatic bile duct cancer or gallbladder cancer |
US10525083B2 (en) | 2016-10-07 | 2020-01-07 | Novartis Ag | Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain |
BR112019011025A2 (en) | 2016-12-03 | 2019-10-08 | Juno Therapeutics Inc | T cell modulation methods |
WO2018106738A1 (en) | 2016-12-05 | 2018-06-14 | Massachusetts Institute Of Technology | Brush-arm star polymers, conjugates and particles, and uses thereof |
KR102019913B1 (en) * | 2017-03-24 | 2019-09-09 | 재단법인 목암생명과학연구소 | Anti-ceacam1 antibody and use thereof |
WO2018174629A1 (en) * | 2017-03-24 | 2018-09-27 | Mogam Institute For Biomedical Research | Anti-ceacam1 antibody and use thereof |
US20200179511A1 (en) | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
US11413310B2 (en) | 2017-06-02 | 2022-08-16 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
MX2019015155A (en) | 2017-06-29 | 2020-08-03 | Juno Therapeutics Inc | Mouse model for assessing toxicities associated with immunotherapies. |
WO2019081983A1 (en) | 2017-10-25 | 2019-05-02 | Novartis Ag | Antibodies targeting cd32b and methods of use thereof |
WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
MA49911A (en) | 2017-11-01 | 2020-06-24 | Juno Therapeutics Inc | ANTIBODIES AND CHEMERICAL ANTIGENIC RECEPTORS SPECIFIC TO THE B-LYMPHOCYTE MATURATION ANTIGEN |
MA50860A (en) | 2017-11-01 | 2020-09-09 | Juno Therapeutics Inc | CHEMERICAL RECEPTERS OF ANTIGEN AGAINST B-CELL MATURATION ANTIGEN AND CODING POLYNUCLEOTIDES |
US12006356B2 (en) | 2017-12-15 | 2024-06-11 | Juno Therapeutics, Inc. | Anti-CCT5 binding molecules and chimeric antigen receptors comprising the same |
US20210069246A1 (en) | 2018-01-31 | 2021-03-11 | Celgene Corporation | Combination therapy using adoptive cell therapy and checkpoint inhibitor |
WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
WO2019213282A1 (en) | 2018-05-01 | 2019-11-07 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
SG11202011830SA (en) | 2018-06-13 | 2020-12-30 | Novartis Ag | Bcma chimeric antigen receptors and uses thereof |
US20210347851A1 (en) | 2018-09-28 | 2021-11-11 | Novartis Ag | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies |
US20220047633A1 (en) | 2018-09-28 | 2022-02-17 | Novartis Ag | Cd22 chimeric antigen receptor (car) therapies |
MX2021005022A (en) | 2018-11-01 | 2021-09-08 | Juno Therapeutics Inc | Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d). |
KR20210113169A (en) | 2018-11-01 | 2021-09-15 | 주노 쎄러퓨티크스 인코퍼레이티드 | Treatment method using chimeric antigen receptor specific for Β cell maturation antigen |
BR112021009420A2 (en) | 2018-11-16 | 2021-11-23 | Juno Therapeutics Inc | Engineered t-cell dosing methods for the treatment of b-cell malignancies |
US20220088070A1 (en) | 2018-11-30 | 2022-03-24 | Juno Therapeutics, Inc. | Methods for treatment using adoptive cell therapy |
AU2019393077A1 (en) * | 2018-12-07 | 2021-07-29 | The Brigham And Women's Hospital, Inc. | Humanized and affinity-matured anti-CEACAM1 antibodies |
US11377494B2 (en) | 2018-12-20 | 2022-07-05 | Albert Einstein College Of Medicine | Antagonist antibodies against human immune checkpoint CEACAM1 (CD66a) and formulations, kits, and methods of use thereof |
KR102166982B1 (en) * | 2019-01-24 | 2020-10-16 | 가톨릭대학교 산학협력단 | Correlation of CEACAM1 and EpCAM in liver cancer and Methods for providing information for liver cancer therapeutic effect using using the same |
EP3917570A1 (en) | 2019-01-29 | 2021-12-08 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1) |
CN114746119A (en) | 2019-09-27 | 2022-07-12 | 詹森生物科技公司 | anti-CEACAM antibodies and uses thereof |
CN114945382A (en) | 2019-11-26 | 2022-08-26 | 诺华股份有限公司 | CD19 and CD22 chimeric antigen receptors and uses thereof |
US20230149462A1 (en) | 2020-04-10 | 2023-05-18 | Juno Therapeutics, Inc. | Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen |
WO2022007283A1 (en) * | 2020-07-08 | 2022-01-13 | 深圳霁因生物医药转化研究院 | Kit and method for diagnosing disease associated with abnormal fap expression, and computer readable storage medium |
CN112501205B (en) * | 2021-02-09 | 2021-05-25 | 百奥赛图(北京)医药科技股份有限公司 | Construction method and application of CEACAM1 gene humanized non-human animal |
TW202307210A (en) | 2021-06-01 | 2023-02-16 | 瑞士商諾華公司 | Cd19 and cd22 chimeric antigen receptors and uses thereof |
WO2023250400A1 (en) | 2022-06-22 | 2023-12-28 | Juno Therapeutics, Inc. | Treatment methods for second line therapy of cd19-targeted car t cells |
WO2024031091A2 (en) | 2022-08-05 | 2024-02-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for gprc5d and bcma |
WO2024100663A1 (en) | 2022-11-10 | 2024-05-16 | Famewave Ltd. | Anti carcinoembryonic antigen-related cell adhesion molecule 1 (ceacam1) antibodies for inhibition of neutrophil extracellular traps (net)-mediated activities |
WO2024129778A2 (en) | 2022-12-13 | 2024-06-20 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8598322B2 (en) * | 2009-04-30 | 2013-12-03 | Tel Hashomer Medical Research Infrastucture and Services Ltd. | Anti CEACAM1 antibodies and methods of using same |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154600B (en) | 1971-02-10 | 1977-09-15 | Organon Nv | METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES. |
NL154598B (en) | 1970-11-10 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING. |
NL154599B (en) | 1970-12-28 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES, AND TEST PACKAGING. |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
NL171930C (en) | 1972-05-11 | 1983-06-01 | Akzo Nv | METHOD FOR DETERMINING AND DETERMINING BITES AND TEST PACKAGING. |
US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
US4036945A (en) | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4348376A (en) | 1980-03-03 | 1982-09-07 | Goldenberg Milton David | Tumor localization and therapy with labeled anti-CEA antibody |
US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US6013772A (en) | 1986-08-13 | 2000-01-11 | Bayer Corporation | Antibody preparations specifically binding to unique determinants of CEA antigens or fragments thereof and use of the antibody preparations in immunoassays |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
DE69127627T2 (en) | 1990-08-29 | 1998-02-19 | Genpharm Int | Production and Use Non-human transgene heterologous antibodies for production |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
EP1073465B1 (en) | 1998-04-15 | 2005-06-22 | The Brigham And Women's Hospital, Inc. | T cell inhibitory receptor compositions and uses thereof |
DE19852804C1 (en) | 1998-11-16 | 1999-12-23 | Christoph Wagener | Pharmaceutical composition for manipulating angiogenesis |
DE10016877A1 (en) | 2000-04-05 | 2001-10-18 | Scintec Diagnostics Gmbh Zug | (Glyco) proteins with high immunoreactivity and a process for their preparation |
SE0002835D0 (en) * | 2000-08-07 | 2000-08-07 | Karolinska Innovations Ab | Method and kit for production of monoclonal antibodies |
US20040214184A1 (en) | 2001-02-28 | 2004-10-28 | Skubitz Keith M | Small peptides capable of modulating the function of cd66 (ceacam) family members |
US20030022292A1 (en) | 2001-06-07 | 2003-01-30 | Gray-Owen Scott D. | Ligation of CEACAM1 |
US20030211477A1 (en) * | 2002-04-05 | 2003-11-13 | Holmes Kathryn V. | Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) structure and uses thereof in drug identification and screening |
CU23228A1 (en) * | 2002-04-29 | 2007-09-26 | Ct Ingenieria Genetica Biotech | FRAGMENTS OF SPECIFIC ANTIBODIES FOR THE HUMAN CARCINOEMBRIONARY ANTIGEN (CEA) SEQUENCES OF ITS VARIABLE REGIONS AND VECTORS FOR THE MICROBIAL EXPRESSION OF THE SAME |
US20040047858A1 (en) | 2002-09-11 | 2004-03-11 | Blumberg Richard S. | Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof |
CA2501757C (en) | 2002-10-08 | 2012-04-24 | Immunomedics, Inc. | Combination therapy with class iii anti-cea monoclonal antibodies and therapeutic agents |
US7803372B2 (en) | 2002-10-08 | 2010-09-28 | Immunomedics, Inc. | Antibody therapy |
WO2005006958A2 (en) | 2003-07-12 | 2005-01-27 | Isis Pharmaceuticals, Inc. | Modulation of ceacam1 expression |
US8815248B2 (en) | 2005-06-09 | 2014-08-26 | Gal Markel | Modulation of immunity and CEACAM1 activity |
US20060291193A1 (en) | 2005-06-24 | 2006-12-28 | Roy Hill | Illuminating garment system and method of use |
WO2008029271A2 (en) | 2006-02-27 | 2008-03-13 | Gal Markel | Ceacam based antibacterial agents |
US8399703B2 (en) | 2007-07-24 | 2013-03-19 | Daikin Industries, Ltd. | Compound, method for producing the same and method for producing fluoropolymer |
EP2208069A4 (en) | 2007-11-05 | 2012-02-01 | Gal Markel | Ceacam1 based point-of-care cancer diagnostic |
WO2011010309A1 (en) * | 2009-07-21 | 2011-01-27 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | A method of diagnosing cancer |
WO2013054320A1 (en) * | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
BR112015008118A2 (en) | 2012-10-12 | 2017-12-05 | Brigham & Womens Hospital Inc | immune response booster |
-
2010
- 2010-04-29 RU RU2016134843A patent/RU2016134843A/en not_active Application Discontinuation
- 2010-04-29 PL PL10721207T patent/PL2424896T3/en unknown
- 2010-04-29 CA CA2760385A patent/CA2760385C/en active Active
- 2010-04-29 DK DK10721207.8T patent/DK2424896T3/en active
- 2010-04-29 CN CN201080029465.XA patent/CN102482354B/en active Active
- 2010-04-29 WO PCT/IL2010/000348 patent/WO2010125571A1/en active Application Filing
- 2010-04-29 US US13/318,266 patent/US8598322B2/en active Active
- 2010-04-29 SI SI201031069T patent/SI2424896T1/en unknown
- 2010-04-29 RU RU2011148598/10A patent/RU2598710C2/en active
- 2010-04-29 KR KR1020117026290A patent/KR101875227B1/en active IP Right Grant
- 2010-04-29 PL PL15183297T patent/PL2990421T3/en unknown
- 2010-04-29 EP EP10721207.8A patent/EP2424896B1/en active Active
- 2010-04-29 BR BRPI1015350-0A patent/BRPI1015350B1/en active IP Right Grant
- 2010-04-29 LT LTEP15183297.9T patent/LT2990421T/en unknown
- 2010-04-29 JP JP2012507879A patent/JP5726170B2/en active Active
- 2010-04-29 HU HUE10721207A patent/HUE028294T2/en unknown
- 2010-04-29 ES ES10721207.8T patent/ES2563527T3/en active Active
- 2010-04-29 EP EP15183297.9A patent/EP2990421B1/en active Active
- 2010-04-29 KR KR1020187018477A patent/KR20180077322A/en not_active Application Discontinuation
- 2010-04-29 ES ES15183297.9T patent/ES2668874T3/en active Active
- 2010-04-29 PT PT107212078T patent/PT2424896E/en unknown
- 2010-04-29 AU AU2010243211A patent/AU2010243211B2/en not_active Ceased
-
2012
- 2012-08-03 HK HK12107666.4A patent/HK1167264A1/en not_active IP Right Cessation
-
2013
- 2013-10-23 US US14/061,277 patent/US9261507B2/en active Active
-
2015
- 2015-10-19 HR HRP20151099TT patent/HRP20151099T8/en unknown
-
2016
- 2016-01-08 US US14/990,959 patent/US20160176966A1/en not_active Abandoned
- 2016-07-25 HK HK16108874.6A patent/HK1222862A1/en unknown
-
2017
- 2017-09-26 US US15/715,386 patent/US20180016338A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8598322B2 (en) * | 2009-04-30 | 2013-12-03 | Tel Hashomer Medical Research Infrastucture and Services Ltd. | Anti CEACAM1 antibodies and methods of using same |
US9261507B2 (en) * | 2009-04-30 | 2016-02-16 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Anti CEACAM1 antibodies and methods of using same |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20180016338A1 (en) | Anti ceacam1 antibodies and methods of using same | |
US20210070884A1 (en) | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) | |
US8268308B2 (en) | Means for the diagnosis and therapy of CTCL | |
AU2007318483B2 (en) | Anti-human Dlk-1 antibody showing anti-tumor activity in vivo | |
HUE026846T2 (en) | Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same | |
EP2561356B1 (en) | MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES | |
US9303086B2 (en) | Anti-hDlk-1 antibody having an antitumor activity in vivo | |
KR20190091483A (en) | Anti-PCNA Monoclonal Antibodies and Uses thereof | |
JP7165855B2 (en) | Use for prevention and treatment of myeloid-derived suppressor cell-related diseases | |
MARKEL et al. | Patent 2760385 Summary | |
CN118215680A (en) | Multispecific antibodies for use in the treatment of disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |